0001144204-17-058708.txt : 20171114 0001144204-17-058708.hdr.sgml : 20171114 20171114100540 ACCESSION NUMBER: 0001144204-17-058708 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171114 DATE AS OF CHANGE: 20171114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASI Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0000895051 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581959440 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-20713 FILM NUMBER: 171198943 BUSINESS ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-864-2600 MAIL ADDRESS: STREET 1: 9620 MEDICAL CENTER DR STREET 2: STE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ENTREMED INC DATE OF NAME CHANGE: 19960415 10-Q 1 tv478651_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to _____________.

Commission file number 0-20713

CASI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	58-1959440
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

9620 Medical Center Drive, Suite 300

Rockville, Maryland

(Address of principal executive offices)

20850

(Zip code)

(240) 864-2600

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES x NO ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES x NO ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨	Accelerated filer ¨	Non-accelerated filer ¨	Smaller reporting company þ
			Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ¨ NO x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most recent practicable date.

Class		Outstanding at November 6, 2017
Common Stock $.01 Par Value		65,066,564

CASI PHARMACEUTICALS, INC.

Table of Contents

		PAGE
PART I. FINANCIAL INFORMATION

Item 1 —	Consolidated Financial Statements

Condensed Consolidated Balance Sheets as of September 30, 2017 (unaudited) and December 31, 2016		4

Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2017 and 2016 (unaudited)		5

Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 (unaudited)		6

Notes to Condensed Consolidated Financial Statements (unaudited)		7

Item 2 —	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3 —	Quantitative and Qualitative Disclosures About Market Risk	20

Item 4 —	Controls and Procedures	21

Part II. OTHER INFORMATION

Item 1 —	Legal Proceedings	21

Item 1A —	Risk Factors	21

Item 2 —	Unregistered Sales of Equity Securities and Use of Proceeds	21

Item 3 —	Defaults Upon Senior Securities	21

Item 4 —	Removed and Reserved	21

Item 5 —	Other Information	21

Item 6 —	Exhibits	22

EXHIBIT INDEX		23

SIGNATURES		24

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements also may be included in other statements that we make. All statements that are not descriptions of historical facts are forward-looking statements. These statements can generally be identified by the use of forward-looking terminology such as “believes,” “expects,” “intends,” “may,” “will,” “should,” or “anticipates” or similar terminology. These forward-looking statements include, among others, statements regarding the timing of our clinical trials, our cash position and future expenses, and our future revenues.

Our forward-looking statements are based on information available to us today, and we will not update these statements.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances; the difficulty of executing our business strategy in China; our inability to predict when or if our product candidates will be approved for marketing by the China Food and Drug Administration authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical and early clinical models are not necessarily indicative of later clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission (“SEC”), which are available at www.sec.gov.

PART I. FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

CASI Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

	September 30, 2017			December 31, 2016
	(Unaudited)			(Note 1)
ASSETS
Current assets:
Cash and cash equivalents	$	21,640,068		$	27,092,928
Prepaid expenses and other		441,818			355,891
Total current assets		22,081,886			27,448,819

Property and equipment, net		566,020			229,591
Other assets		68,244			34,485
Total assets	$	22,716,150		$	27,712,895

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,203,965		$	1,064,626
Accrued liabilities		302,644			250,950
Note payable, net of discount		1,496,885			-
Total current liabilities		3,003,494			1,315,576

Note payable, net of discount		-			1,491,278
Contingent rights derivative liability		4,134,931			4,122,266
Total liabilities		7,138,425			6,929,120

Commitments and contingencies

Stockholders’ equity:
Convertible preferred stock, $1.00 par value; 5,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2017 and December 31, 2016		-			-
Common stock, $.01 par value: 170,000,000 shares authorized; 60,276,119 shares issued at September 30, 2017 and December 31, 2016		602,760			602,760
Additional paid-in capital		470,663,323			470,147,086
Treasury stock, at cost: 79,545 shares held		(8,034,244	)		(8,034,244	)
Accumulated deficit		(447,654,114	)		(441,931,827	)
Total stockholders’ equity		15,577,725			20,783,775
Total liabilities and stockholders’ equity	$	22,716,150		$	27,712,895

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30, 2017			September 30, 2016			September 30, 2017			September 30, 2016
Revenues:
Product sales	$	-		$	-		$	-		$	-

Costs and expenses:
Research and development		970,989			1,013,929			3,747,683			3,395,362
General and administrative		625,878			676,927			1,961,463			3,356,804
		1,596,867			1,690,856			5,709,146			6,752,166

Interest expense, net		546			5,614			476			23,140
Change in fair value of contingent rights		16,110			(2,978	)		12,665			4,422

Net loss	$	(1,613,523	)	$	(1,693,492	)	$	(5,722,287	)	$	(6,779,728	)

Net loss per share (basic and diluted)	$	(0.03	)	$	(0.03	)	$	(0.10	)	$	(0.15	)
Weighted average number of common shares outstanding (basic and diluted)		60,196,574			49,227,983			60,196,574			44,132,599

See accompanying condensed notes.

CASI Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months Ended
	September 30, 2017			September 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(5,722,287	)	$	(6,779,728	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		69,420			47,963
Gain on disposal of assets		-			(12,461	)
Stock-based compensation expense		516,237			2,201,401
Non-cash interest		5,607			21,015
Change in fair value of contingent rights		12,665			4,422
Changes in operating assets and liabilities:
Prepaid expenses and other		(119,686	)		40,840
Accounts payable		139,339			34,793
Accrued liabilities		51,694			(7,486	)
Net cash used in operating activities		(5,047,011	)		(4,449,241	)

CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of furniture and equipment		-			158,446
Purchases of furniture and equipment		(405,849	)		(159,244	)
Net cash used in investing activities		(405,849	)		(798	)

CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuance costs		-			(72,087	)
Proceeds from sale of common stock		-			17,254,341
Proceeds from sale of common stock to be issued		-			6,274,000
Net cash provided by financing activities		-			23,456,254

Net (decrease) increase in cash and cash equivalents		(5,452,860	)		19,006,215
Cash and cash equivalents at beginning of period		27,092,928			5,131,114
Cash and cash equivalents at end of period	$	21,640,068		$	24,137,329

Supplemental disclosure of cash flow information:

Non-cash financing activity:
Partial settlement of contingent rights derivative	$	-		$	3,232,502

See accompanying condensed notes.

CASI PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2017 (unaudited)

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of CASI Pharmaceuticals, Inc. and its subsidiaries (“CASI” or “the Company”), Miikana Therapeutics, Inc. (“Miikana”) and CASI Pharmaceuticals (Beijing) Co., Ltd. (“CASI China”). The Company previously operated under a different name prior to restructuring its business in 2012 in connection with an investment led by one of the Company’s largest stockholders. CASI China is a non-stock Chinese entity with 100% of its interest owned by CASI. CASI China received approval for a business license from the Beijing Industry and Commercial Administration in August 2012 and has operating facilities in Beijing. All inter-company balances and transactions have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, such condensed consolidated financial statements do not include all of the information and disclosures required by U.S. generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The accompanying December 31, 2016 financial information was derived from the Company’s audited financial statements in the Annual Report on Form 10-K for the year ended December 31, 2016. Operating results for the three and nine month periods ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in its Form 10-K for the year ended December 31, 2016.

Liquidity Risks and Management’s Plans

Since inception, the Company has incurred significant losses from operations and has incurred an accumulated deficit of approximately $447.7 million. The Company restructured its business in 2012 in connection with an investment led by one of the Company’s largest stockholders, followed by implementation of a name change to reflect its core mission and business strategy. The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical activities. In 2016, the Company received $28.1 million from strategic financings (“2016 Strategic Financings”). In October 2017, the Company entered into securities purchase agreements for an approximately $23.8 million strategic financing. The Company held its initial closing on October 17, 2017 and second closing on October 23, 2017 and received approximately $14.6 million (collectively, the “Closings”) (see Note 5). The Company expects to close on the remaining $9.2 million (“Final Closing”) during November 2017. Net proceeds will be used to support the Company’s business development activities, advance the development of the Company’s pipeline, and for other general corporate purposes. As a result of the Closings and the 2016 Strategic Financings, the Company believes that it has sufficient resources to fund its operations for at least the twelve months subsequent to November 14, 2017. As of September 30, 2017, approximately $3.8 million of the Company’s cash balance was held by CASI China. The Company intends to continue to exercise tight controls over operating expenditures and will continue to pursue opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive capital raising arrangements in China to support the Company’s dual-country approach to drug development.

License Arrangements

The Company has certain product rights and perpetual exclusive licenses from Spectrum Pharmaceuticals, Inc. and certain of its affiliates (together referred to as “Spectrum”) to develop and commercialize the following commercial oncology drugs and drug candidates in the greater China region (which includes China, Taiwan, Hong Kong and Macau) (the “Territories”):

EVOMELA^® (melphalan) for Injection (“Evomela”);

MARQIBO^® (vinCRIStine sulfate LIPOSOME injection) (“Marqibo”); and

ZEVALIN^® (ibritumomab tiuxetan) (“Zevalin”).

CASI is responsible for developing and commercializing these three drugs in the Territories, including the submission of import drug registration applications and conducting confirmatory clinical trials as needed.

The Company is in various stages of the regulatory and development process to obtain marketing approval for EVOMELA^®, MARQIBO^®, and ZEVALIN^® in its territorial region, with ZEVALIN^® commercially available in Hong Kong. In January 2016, the China Food and Drug Administration (CFDA) accepted for review the Company’s import drug registration application for MARQIBO^® and currently is in the quality testing phase of the regulatory process. On March 10, 2016, Spectrum received notification from the U.S. Food and Drug Administration (FDA) of the grant of approval of its New Drug Application (NDA) for EVOMELA^® primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. In December 2016, the CFDA accepted for review the Company’s import drug registration application for EVOMELA^® and in 2017 has granted priority review of the import drug registration clinical trial application (CTA), which currently is in the quality testing phase of the regulatory process. The CFDA filing and review of CASI’s ZEVALIN^® import drug CTA is in process. The ZEVALIN^® antibody kit and the radioactive Yttrium-90 component of the CTA require separate submissions to the CFDA, of which the first part is currently under review and the latter part is in the submission process.

Note Payable

As part of the license arrangements with Spectrum (see Note 2), the Company issued to Spectrum a $1.5 million 0.5% secured promissory note originally due March 17, 2016 which was subsequently amended and extended to March 17, 2018. All other terms remain the same. The promissory note was recorded initially at its fair value, giving rise to a discount of approximately $136,000; the promissory note is presented as note payable, net of discount in the accompanying condensed consolidated balance sheets. For the nine months ended September 30, 2017 and 2016, the Company recognized $5,607 and $21,015 of non-cash interest expense, respectively, related to the amortization of the debt discount, using the effective interest rate method.

Fair Value Measurements

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:

Level 1, defined as observable inputs such as quoted prices in active markets for identical assets;

Level 2, defined as observable inputs other than Level 1 prices such as quoted prices for similar assets; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company performs a detailed analysis of its assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair values are based on period-end statements supplied by the various banks and brokers that held the majority of the Company’s funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, and other current assets and liabilities) approximates their carrying values because of their short-term nature.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:

As partial consideration for the acquisition from Spectrum, the Company issued certain contingent rights (“Contingent Rights”) to purchase additional shares of its common stock, which Contingent Rights expire upon the occurrence of certain events. The Contingent Rights issued to Spectrum in connection with the license arrangements (see Note 2) are considered derivative liabilities and were recorded initially at their estimated fair value, and are marked to market each reporting period until settlement. The fair value of the Contingent Rights was measured using Level 3 unobservable inputs; the unobservable inputs include estimates of the Company’s future capital requirements, and the timing, probability, size and characteristics of those capital raises, among other inputs. Generally, if the estimates of the size and probability of the Company’s future capital requirements increase, the fair value of the Contingent Rights will also increase.

The following table presents the Company’s financial liabilities accounted for at fair value on a recurring basis as of September 30, 2017 and December 31, 2016 by level within the fair value hierarchy:

	As of September 30, 2017
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	4,134,931	$	4,134,931

	As of December 31, 2016
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	4,122,266	$	4,122,266

The following table presents the changes in the Company’s financial liabilities accounted for at fair value on a recurring basis using Level 3 unobservable inputs:

December 31, 2016	$	4,122,266
Change in fair value of Contingent Rights		12,665
Balance at September 30, 2017	$	4,134,931

As a result of the Closings (see Note 5), the Company has recorded a reduction to the Contingent Rights derivative liability and an increase to additional paid-in capital of $2,762,979 in October 2017 which will be reflected in the Company’s December 31, 2017 consolidated financial statements.

Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:

The promissory note issued to Spectrum in connection with the license arrangements (see Notes 2 and 3) was initially recorded at its fair value using Level 3 unobservable inputs including primarily the Company’s estimated incremental borrowing rate as provided by a commercial lending institution.

Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:

The Company does not have any non-financial assets and liabilities that are measured at fair value on a recurring basis.

Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:

The Company measures its long-lived assets, including property and equipment, at fair value on a non-recurring basis. These assets are recognized at fair value when they are deemed to be impaired. No such fair value impairment was recognized for the nine months ended September 30, 2017 and 2016.

Stockholders’ Equity

Securities Purchase Agreements

On October 13, 2017, the Company entered into securities purchase agreements (the “Securities Purchase Agreements”) with certain institutional investors, accredited investors and current stockholders (collectively, the “Purchasers”) pursuant to which the Company agreed to sell 7,951,865 shares of its common stock and warrants exercisable for up to 1,590,373 shares of its common stock (exclusive of the Agent Warrants described below) in a registered direct offering (the “Offering”) for gross proceeds of $23,855,595. The shares and warrants are being sold together, consisting of one share of common stock and a warrant to purchase 0.20 shares of common stock for each share of common stock purchased, at a combined offering price of $3.00. The warrants will be exercisable beginning on April 17, 2018 and will expire on April 17, 2020. The warrants have an exercise price of $3.75 per share.

The Company held its initial closing on October 17, 2017 and second closing on October 23, 2017 (collectively, the “Closings”) and received approximately $14.6 million and yielded approximately $14.3 million after offering expenses. The Closings resulted in the issuance of 4,869,990 shares of common stock. The Company expects to close on the remaining $9.2 million in November 2017, subject to satisfaction of customary closing conditions.

In connection with the Offering, the Company issued to its placement agent or its designees warrants to purchase 48,133 shares of common stock at an exercise price of $3.75 per share of common stock (the “Agent Warrants”), representing the number of warrants equal to an aggregate of 4% of the number of shares sold to investors placed by the placement agent in the Offering, excluding investments made by certain China-focused investors that were placed by the Company. The Agent Warrants will become exercisable on April 17, 2018 and will expire on April 17, 2019.

Net Loss Per Share

Net loss per share (basic and diluted) was computed by dividing net loss attributable to common shareholders by the weighted average number of shares of common stock outstanding. Outstanding stock options and warrants totaling 12,242,004 and 4,686,760 as of September 30, 2017, respectively, were anti-dilutive and, therefore, were not included in the computation of weighted average shares used in computing diluted loss per share.

Share-Based Compensation

The Company has adopted incentive and nonqualified stock option plans for executive, scientific and administrative personnel of the Company as well as outside directors and consultants. In June 2017, the Company’s shareholders approved an amendment to the 2011 Long-Term Incentive Plan, increasing the number of shares reserved for issuance from 11,230,000 to 14,230,000 shares of common stock to be available for grants and awards. As of September 30, 2017, there are 12,242,004 shares issuable under options previously granted and currently outstanding, with exercise prices ranging from $0.86 to $13.75. In 2017, the Company awarded options to employees, covering up to 2,725,000 shares, in which vesting is subject to achievement of certain performance milestones. Options granted under the plans generally vest over periods varying from immediately to one to three years, are not transferable and generally expire ten years from the date of grant. As of September 30, 2017, 2,355,358 shares remained available for grant under the Company’s 2011 Long-Term Incentive Plan.

The Company records compensation expense associated with stock options and other equity-based compensation in accordance with provisions of authoritative guidance. Compensation costs are recognized over the requisite service period, which is generally the option vesting term of up to three years. Awards with performance conditions will be expensed if it is probable that the performance condition will be achieved. For the nine months ended September 30, 2017 and 2016, $30,500 and $10,100, respectively was expensed for share awards with performance conditions that became probable during that period.

The Company’s net loss for the nine months ended September 30, 2017 and 2016 includes non-cash compensation expense of $516,237 and $2,201,401, respectively, related to the Company’s share-based compensation awards. The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:

	Nine Month Period Ended September 30,
	2017		2016
Research and development	$	225,342	$	578,626
General and administrative		290,895		1,622,775
Share-based compensation expense	$	516,237	$	2,201,401
Net share-based compensation expense, per common share:
Basic and diluted	$	0.01	$	0.05

The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of stock options granted to employees. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award.

Following are the weighted-average assumptions used in valuing the stock options granted during the nine-month periods ended September 30, 2017 and 2016:

	Nine Month Period Ended September 30,
	2017			2016
Expected volatility		78.92	%		83.03	%
Risk-free interest rate		1.97	%		1.31	%
Expected term of option		6.34 years			5.41 years
Forfeiture rate		-			3.00	%*
Expected dividend yield		0.00	%		0.00	%

* - In 2016, authoritative guidance required forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the nine-month period ended September 30, 2016, forfeitures were estimated at 3%.

The weighted average fair value of stock options granted during the nine-month periods ended September 30, 2017 and 2016 were $0.73 and $0.75, respectively.

A summary of the Company’s stock option plans and of changes in options outstanding under the plans for the nine months ended September 30, 2017 is as follows:

	Number of Options			Weighted Average Exercise Price
Outstanding at January 1, 2017		9,535,306		$	1.57
Granted		3,699,500		$	1.04
Exercised		-		$	-
Expired		(992,802	)	$	1.64
Forfeited		-		$	-
Outstanding at September 30, 2017		12,242,004		$	1.41
Exercisable at September 30, 2017		8,330,511		$	1.59

There were no option exercises during the nine months ended September 30, 2017 or 2016.

Income Taxes

At December 31, 2016, the Company had a $3.1 million unrecognized tax benefit. The Company recorded a full valuation allowance on the net deferred tax asset recognized in the consolidated financial statements as of December 31, 2016.

During the nine months ended September 30, 2017, there were no material changes to the measurement of unrecognized tax benefits in various taxing jurisdictions. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense.

The tax returns for all years in the Company’s major tax jurisdictions are not settled as of September 30, 2017. Due to the existence of tax attribute carryforwards (which are currently offset by a full valuation allowance), the Company treats all years’ tax positions as unsettled due to the taxing authorities’ ability to modify these attributes.

Related Party Transactions

In April and June 2017, under supply agreements with Spectrum, the Company received shipments of EVOMELA^® and MARQIBO^®, respectively, in China for quality testing purposes to support CASI’s application for import drug registration. The CEO of Spectrum is also a board member of CASI. The total cost of the materials was approximately $477,000 which is included in research and development expense for the nine months ended September 30, 2017.

The Company utilizes the services of Crown Biosciences, Inc. (“Crown Bio”) to perform certain research and development testing. The CEO of Crown Bio is also a board member of CASI. All amounts payable to Crown Bio for services provided have been paid as of September 30, 2017. The research and development expense recognized for the services provided for the nine months ended September 30, 2016 was $28,648. There were no research and development services provided by Crown Bio for the nine months ended September 30, 2017.

10.

New Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact the Company’s condensed consolidated financial statements.

In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-01, Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The accounting standard primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, it includes a clarification related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2017. Early adoption is permitted for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company does not expect that the adoption of ASU 2016-01 will have a material impact on the consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 supersedes existing lease guidance, including Accounting Standards Codification (ASC) 840 - Leases. Among other things, the new standard requires recognition of a right-of-use asset and liability for future lease payments for contracts that meet the definition of a lease. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. The standard must be applied using a modified retrospective approach. The Company is currently evaluating the effect that the adoption of this ASU will have on its consolidated financial statements.

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting. ASU 2017-09 provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions, or award classification and would not be required if the changes are considered non-substantive. The Company is evaluating the impact of ASU 2017-09.

There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company’s financial position, results of operations or cash flows.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

OVERVIEW

We are a U.S. based, late-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on commercialization in China. We intend to execute our plan to become a leading fully-integrated pharmaceutical company with a substantial commercial business in China. We are headquartered in Rockville, Maryland with established China operations that are growing as we continue to further in-license products for our pipeline.

Our product pipeline features (1) EVOMELA^®, MARQIBO^® and ZEVALIN^®, all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the regulatory and clinical process for market approval in China, (2) CASI-001 and CASI-002, proprietary preclinical candidates in immune-oncology, and (3) our proprietary drug candidate, ENMD-2076, ongoing in one Phase 2 clinical study.

Our China rights to EVOMELA^® (melphalan) for Injection, MARQIBO^® (vinCRIStine sulfate LIPOSOME injection) and ZEVALIN^® (ibritumomab tiuxetan) were previously licensed from our partner Spectrum Pharmaceuticals, Inc. Based on the U.S. FDA’s approval of these three licensed products, we are pursuing the Import Drug registration path for approval in China.

We believe our pipeline reflects a risk-balanced approach between products in various stages of development, and between products that we develop ourselves and those that we develop with our partners for the China regional market. We intend to continue building a significant product pipeline of innovative drug candidates that we will commercialize in China and collaborate with partners for the rest of the world. For in-licensed products, the Company uses a market-oriented approach to identify pharmaceutical candidates that we believe have the potential for gaining widespread market acceptance, either globally or in China, and for which development can be accelerated under the Company’s drug development strategy. For ENMD-2076, our current development is focused on niche and orphan indications.

Our primary research and development focus is on oncology therapeutics. Our strategy is to develop innovative drugs that are potential first-in-class or market-leading compounds for treatment of cancer. The implementation of our plans will include leveraging our resources in both the United States and China. In order to capitalize on the drug development and capital resources available in China, the Company is conducting business in China through its wholly-owned China-based subsidiary that will execute the China portion of the Company’s drug development strategy, including conducting clinical trials in China, pursuing local funding opportunities and strategic collaborations, and implementing the Company’s plan to build a leading commercial business in China.

Since inception, the Company has incurred significant losses from operations and has incurred an accumulated deficit of $447.7 million. The Company restructured its business in 2012 in connection with an investment led by one of the Company’s largest stockholders, followed by implementation of a name change to reflect its core mission and business strategy. The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical activities. In 2016, the Company received $28.1 million from strategic financings (“2016 Strategic Financings”). In October 2017, the Company entered into securities purchase agreements for an approximately $23.8 million strategic financing. The Company held its initial closing on October 17, 2017 and second closing on October 23, 2017 and received approximately $14.6 million (collectively, the “Closings”). The Company expects to close on the remaining $9.2 million (“Final Closing”) during November 2017. Net proceeds will be used to support the Company’s business development activities, advance the development of the Company’s pipeline, and for other general corporate purposes. As a result of the Closings and the 2016 Strategic Financings, the Company believes that it has sufficient resources to fund its operations for at least the twelve months subsequent to November 14, 2017. We intend to continue to exercise tight controls over operating expenditures. In developing drug candidates, we intend to use and leverage resources available to us in both the United States and China. We intend to pursue additional financing opportunities as well as opportunities to raise capital through forms of non- or less- dilutive arrangements, such as partnerships and collaborations with organizations that have capabilities and/or products that are complementary to our capabilities and products in order to continue the development of our product candidates that we intend to pursue to commercialization. However, there can be no assurance that adequate additional financing under such arrangements will be available to us on terms that we deem acceptable, if at all.

Additional funds raised by issuing equity securities may result in dilution to existing stockholders.

CRITICAL ACCOUNTING POLICIES AND THE USE OF ESTIMATES

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Our critical accounting policies, including the items in our financial statements requiring significant estimates and judgments, are as follows:

Research and Development - Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with preclinical testing and clinical trials of our product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses. Research and development costs are expensed as incurred.

Expenses for Clinical Trials - Expenses for clinical trials are incurred from planning through patient enrollment to reporting of the data. We estimate expenses incurred for clinical trials that are in process based on patient enrollment and based on clinical data collection and management. Costs that are associated with patient enrollment are recognized as each patient in the clinical trial completes the enrollment process. Estimated clinical trial costs related to enrollment can vary based on numerous factors, including expected number of patients in trials, the number of patients that do not complete participation in a trial, and when a patient drops out of a trial. Costs that are based on clinical data collection and management are recognized in the reporting period in which services are provided. In the event of early termination of a clinical trial, we accrue an amount based on estimates of the remaining non-cancelable obligations associated with winding down the clinical trial.

Stock-Based Compensation - All share-based payment transactions are recognized in the consolidated financial statements at their fair values. Compensation expense associated with service, performance, market condition-based stock options and other equity-based compensation is recorded in accordance with provisions of authoritative guidance. The fair value of awards whose fair values are calculated using the Black-Scholes option pricing model is generally being amortized on a straight-line basis over the requisite service period and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period. The fair value of awards with market conditions, which are valued using a binomial model, is being amortized based upon the estimated derived service period. Share-based awards granted to employees with a performance condition are measured based on the probable outcome of that performance condition during the requisite service period. Such an award with a performance condition will be expensed if it is probable that a performance condition will be achieved. For the nine months ended September 30, 2017 and 2016, $30,500 and $10,100, respectively was expensed for share awards with performance conditions that became probable during that period. Using the straight-line expense attribution method over the requisite service period, which is generally the option vesting term ranging from immediately to one to three years, share-based compensation expense recognized for the nine months ended September 30, 2017 and 2016 totaled approximately $516,000 and $2,201,000, respectively.

The determination of fair value of stock-based payment awards on the date of grant using the Black-Scholes valuation model is affected by our stock price, as well as the input of other subjective assumptions. These assumptions include, but are not limited to, the expected forfeiture rate and expected term of stock options and our expected stock price volatility over the term of the awards. Changes in the assumptions can materially affect the fair value estimates.

Any future changes to our share-based compensation strategy or programs would likely affect the amount of compensation expense recognized.

Fair Value Measurements - At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3 in accordance with the hierarchy established by U.S. GAAP. As of September 30, 2017, we remeasured the Contingent Rights and will continue to do so at every balance sheet date and upon partial settlements until completely settled. In measuring the fair value of the financial instrument we used Level 3 unobservable inputs, including such inputs as our estimated borrowing rate and our future capital requirements, and the timing, probability, size and characteristics of those capital raises, among other inputs.

RESULTS OF OPERATIONS

For the Three and Nine Months Ended September 30, 2017 and September 30, 2016.

Revenues and Cost of Product Sales. There were no revenues recorded for the three or nine months ended September 30, 2017 and September 30, 2016.

Research and Development Expenses. Our research and development expenses for the three and nine months ended September 30, 2017 totaled approximately $971,000 and $3,748,000, respectively. Research and development expenses for the corresponding 2016 periods were $1,014,000 and $3,395,000, respectively. Included in our R&D expenses for the three-month period ended September 30, 2017 are direct project costs of $148,000 for ENMD-2076, $188,000 for drugs in-licensed from Spectrum, and $279,000 for preclinical development activities in China. The 2016 research and development expenses for the comparable period included $452,000 for ENMD-2076, $65,000 for drugs in-licensed from Spectrum, and $229,000 for preclinical development activities in China. Research and development expenses totaling $3,748,000 for the nine-month period ended September 30, 2017 included direct project costs of $697,000 related to ENMD-2076, $1,100,000 for drugs in-licensed from Spectrum, and $837,000 for preclinical development activities in China. The 2016 research and development expenses for the comparable period totaled $3,395,000 and included $1,269,000 for ENMD-2076, $375,000 for drugs in-licensed from Spectrum, and $585,000 for preclinical development activities in China. The decrease in research and development costs in the three month period ended September 30, 2017, as compared to the same period in 2016, primarily reflects lower costs for the FLC trial due to the timing of patient enrollment, offset by increased costs associated with our China operations. The overall increase in research and development costs in the nine month period ended September 30, 2017, as compared to same period in 2016, primarily reflects higher costs associated with the quality testing phase of the regulatory review of MARQIBO^® and EVOMELA^® in 2017.

At September 30, 2017, and, since acquired, accumulated direct project expenses for ENMD-2076 totaled $28,352,000, $2,033,000 for drugs in-licensed from Spectrum, and for preclinical development activities in China, accumulated project expenses totaled $2,892,000. Our research and development expenses also include non-cash stock-based compensation totaling $54,000 and $225,000 for the three and nine months ended September 30, 2017, respectively, and $61,000 and $579,000 for the corresponding 2016 periods, respectively. The balance of our research and development expenditures includes facility costs and other departmental overhead, regulatory expenses associated with import drug registration applications in China for the drugs in-licensed from Spectrum, and expenditures related to the non-clinical support of our programs.

We expect the majority of our research and development expenses in 2017 to be devoted to advancing our in-licensed products towards market approval in China, our early-stage candidates in preclinical development, and the development of our ENMD-2076 program. We expect our expenses in 2017 to increase based on our clinical development plan. Completion of clinical development may take several years or more, but the length of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate.

We estimate that clinical trials of the type we generally conduct are typically completed over the following timelines:

Global FDA Trial:

*CLINICAL PHASE*		*ESTIMATED* *COMPLETION* *PERIOD*
Phase 1		1-2 Years
Phase 2		2-3 Years
Phase 3		2-4 Years

Local CFDA Trial:

*CLINICAL PHASE*		*ESTIMATED* *COMPLETION* *PERIOD*
Phase 1		1 Year
Phase 2		2 Years
Phase 3		2-3 Years

The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during the clinical trial protocol, including, among others, the following:

the number of patients that ultimately participate in the trial;

the duration of patient follow-up that seems appropriate in view of the results;

the number of clinical sites included in the trials; and

the length of time required to enroll suitable patient subjects.

We test our potential product candidates in numerous preclinical studies to identify indications for which they may be product candidates. We may conduct multiple clinical trials to cover a variety of indications for each product candidate. As we obtain results from trials, we may elect to discontinue clinical trials for certain indications in order to focus our resources on more promising indications.

Our proprietary product candidates have also not yet achieved regulatory approval, which is required before we can market them as therapeutic products. In order to proceed to subsequent clinical trial stages and to ultimately achieve regulatory approval, regulatory agencies must conclude that our clinical data establish safety and efficacy. Historically, the results from preclinical testing and early clinical trials have often not been predictive of results obtained in later clinical trials. A number of new drugs and biologics have shown promising results in clinical trials, but subsequently failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals.

Our business strategy includes being opportunistic with collaborative arrangements with third parties to complete the development and commercialization of our product candidates. In the event that third parties take over the clinical trial process for one of our product candidates, the estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in whole or in part, and how such arrangements would affect our capital requirements.

As a result of the uncertainties discussed above, among others, we are unable to estimate the duration and completion costs of our research and development projects. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. There can be no assurance that we will be able to successfully access external sources of financing in the future. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.

Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with internal and contract preclinical testing and clinical trials of our product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses. Overall research and development expenses decreased to $971,000 during the three months ended September 30, 2017 from $1,014,000 for the corresponding period in 2016. Research and development expenses increased to $3,748,000 during the nine months ended September 30, 2017 from $3,395,000 for the corresponding period in 2016. The fluctuations in research and development expenditures during the three and nine months ended September 30, 2017 were specifically impacted by the following:

Outside Services – In the three-month period ended September 30, 2017, we expended $82,000 on outside service activities versus $58,000 in the same 2016 period. For the nine month period ended September 30, 2017, outside services were $314,000 compared to $175,000 for the same 2016 period. The increase in 2017 as compared to 2016 reflects regulatory costs associated with the import drug registration applications in China for the drugs in-licensed from Spectrum.

Clinical Trial Costs – Clinical trial costs, which include clinical site fees, monitoring costs and data management costs, decreased to $50,000 in the three months ended September 30, 2017 from $340,000 in the three month period ended September 30, 2016. Clinical trial costs for the nine month period ended September 30, 2017 decreased to $375,000 from $899,000 for the comparable 2016 period. The decrease for both periods primarily relates to higher enrollment patient costs and clinical trial management costs associated with our Phase 2 clinical trial in advanced fibrolamellar carcinoma (FLC) during the 2016 period.

Contract Manufacturing Costs – The costs of manufacturing the material used in clinical trials for our product candidates is reflected in contract manufacturing. These costs include bulk manufacturing, encapsulation and fill and finish services, product release costs and storage fees. Contract manufacturing costs for the three months ended September 30, 2017 decreased to $(4,000) from $24,000 during the same period in 2016. For the nine month period ended September 30, 2017, manufacturing costs increased to $620,000 from $196,000 for the comparable 2016 period. The increase primarily reflects costs associated with the purchase of EVOMELA^® in China for quality testing purposes to support CASI’s application for import drug registration in 2017.

Personnel Costs – Personnel costs increased to $591,000 in the three-month period ended September 30, 2017 from $367,000 in the corresponding 2016 period. For the nine-month period ended September 30, 2017, personnel costs increased in 2017 to $1,583,000 from $1,439,000 for the corresponding 2016 period. This variance is attributed to a decrease in non-cash stock-based compensation expense totaling $354,000 during the 2017 period, offset by increased salary and benefit costs associated with employees in China and a new Chief Medical Officer in the U.S. in 2017.

Also reflected in our 2017 research and development expenses for the three-month period ended September 30, 2017 are outsourced consultant costs of $36,000 and facility and related expenses of $125,000. In the corresponding 2016 period, these expenses totaled $71,000 and $73,000, respectively. For the nine month period ended September 30, 2017, outsourced consultant costs were $177,000 and facility and related expenses were $347,000. In the corresponding 2016 period, these expenses totaled $231,000 and $251,000, respectively. The variance in outsourced consultant costs reflect the timing of clinical trial management and evaluation and regulatory activities. The increase in facilities and related expenses for both periods is due to new leased lab space in China in 2017.

General and Administrative Expenses. General and administrative expenses include compensation and other expenses related to finance, business development and administrative personnel, professional services and facilities.

General and administrative expenses decreased to $626,000 in the three-month period ended September 30, 2017 from $677,000 in the corresponding 2016 period. The decrease in the third quarter of 2017, compared to the 2016 period, is primarily related to a decrease in stock-based compensation expense of $52,000. For the nine-month period ended September 30, 2017, general and administrative expenses decreased in 2017 to $1,961,000 from $3,357,000 for the corresponding 2016 period. The decrease in the 2017 period, compared to the 2016 period is primarily related to a decrease in stock-based compensation expense of $1,332,000 primarily related to stock options awarded in connection with the closings of the Company’s strategic financing in 2016.

Interest expense, net. Interest expense, net for three months ended September 30, 2017 and 2016 was $546 and $5,614, respectively. This includes interest on our note payable of $1,875 for both periods; non-cash interest of $1,869 and $7,005, respectively, representing the amortization of the debt discount; offset by interest income of $3,197 and $3,266, respectively. Interest expense, net for the nine months ended September 30, 2017 and 2016 was $476 and $23,140, respectively. This includes interest on our note payable of $5,625 for both periods; non-cash interest of $5,607 and $21,015, respectively, representing the amortization of the debt discount; offset by interest income of $10,756 and $3,500, respectively.

Change in fair value of contingent rights. The Contingent Rights issued to Spectrum in connection with the license arrangements are considered derivative liabilities and were recorded initially at their estimated fair value, and are marked to market each reporting period until settlement. The change in fair value of the Contingent Rights for the three and nine months ended September 30, 2017 was $16,110 and $12,665, respectively. The change in fair value of the Contingent Rights for the three and nine months ended September 30, 2016 was $(2,978) and $4,422, respectively.

LIQUIDITY AND CAPITAL RESOURCES

To date, we have been engaged primarily in research and development activities. As a result, we have incurred and expect to continue to incur operating losses in 2017 and the foreseeable future before we commercialize any products. Based on our current plans, we expect our current available cash and cash equivalents to meet our cash requirements for at least the twelve months subsequent to November 14, 2017.

We will require significant additional funding to fund operations until such time, if ever, we become profitable. We intend to augment our cash balances by pursuing other forms of capital infusion, including strategic alliances or collaborative development opportunities with organizations that have capabilities and/or products that are complementary to our capabilities and products in order to continue the development of our potential product candidates that we intend to pursue to commercialization. If we seek strategic alliances, licenses, or other alternative arrangements, such as arrangements with collaborative partners or others, to raise further financing, we may need to relinquish rights to certain of our existing product candidates, or products we would otherwise seek to develop or commercialize on our own, or to license the rights to our product candidates on terms that are not favorable to us.

We will continue to seek to raise additional capital to fund our research and development and advance our clinical development activities. We intend to explore one or more of the following alternatives to raise additional capital:

selling additional equity securities;

out-licensing product candidates to one or more corporate partners;

completing an outright sale of non-priority assets; and/or

engaging in one or more strategic transactions.

We also will continue to manage our cash resources prudently and cost-effectively.

There can be no assurance that adequate additional financing under such arrangements will be available to us on terms that we deem acceptable, if at all. If additional funds are raised by issuing equity securities, dilution to existing stockholders may result, or the equity securities may have rights, preferences, or privileges senior to those of the holders of our common stock. If we fail to obtain additional capital when needed, we may be required to delay or scale back our clinical development activities.

At September 30, 2017, we had cash of approximately $21.6 million with working capital of approximately $19.1 million. As of September 30, 2017, approximately $3.8 million of the Company’s cash balance was held by CASI China.

FINANCING ACTIVITIES

As discussed above, in 2016 the Company received $28.1 million from the 2016 Strategic Financings. Additionally, as discussed above, on October 13, 2017, the Company entered into Securities Purchase Agreements with certain institutional investors, accredited investors and current stockholders pursuant to which the Company agreed to sell 7,951,865 shares of its common stock and warrants exercisable for up to 1,590,373 shares of its common stock in a registered direct offering for gross proceeds of $23,855,595. The shares and warrants are being sold together, consisting of one share of common stock and a warrant to purchase 0.20 shares of common stock for each share of common stock purchased, at a combined offering price of $3.00. The warrants will be exercisable beginning on April 17, 2018 and will expire on April 17, 2020. The warrants have an exercise price of $3.75 per share.

The Company held its initial closing on October 17, 2017 and second closing on October 23, 2017 and received approximately $14.6 million and yielded approximately $14.3 million after offering expenses. The Closings resulted in the issuance of 4,869,990 shares of common stock. The Company expects to close on the remaining $9.2 million in November 2017, subject to satisfaction of customary closing conditions.

INFLATION AND INTEREST RATE CHANGES

Management does not believe that our working capital needs are sensitive to inflation and changes in interest rates.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The primary objective of our investment activities is to preserve our capital until it is required to fund operations while at the same time maximizing the income we receive from our investments without incurring investment market volatility risk. Our investment income is sensitive to the general level of U.S. interest rates. In this regard, changes in the U.S. interest rates affect the interest earned on our cash and cash equivalents. Due to the short-term nature of our cash and cash equivalent holdings, a 10% movement in market interest rates would not materially impact the total fair market value of our portfolio as of September 30, 2017.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s Chief Executive Officer and Principal Accounting Officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) were effective as of September 30, 2017 to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to the Company’s management, including its Chief Executive Officer and Principal Accounting Officer, as appropriate to allow timely decisions regarding required disclosure.

We believe that a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting that occurred during the quarter ended September 30, 2017 that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are subject in the normal course of business to various legal proceedings in which claims for monetary or other damages may be asserted. Management does not believe such legal proceedings, unless otherwise disclosed herein, are material.

ITEM 1A. RISK FACTORS

For information regarding factors that could affect the Company’s results of operations, financial condition and liquidity, see the risk factors discussion set forth in Item 1A of CASI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and the information under “Special Note Regarding Forward-Looking Statements” included in this report. There have been no material changes to our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4.

REMOVED AND RESERVED

ITEM 5.

OTHER INFORMATION

Not applicable.

ITEM 6.

EXHIBITS

1.1		Engagement Letter, dated as of October 12, 2017, by and between CASI Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (filed as Exhibit 1.1 to our Form 8-K filed on October 19, 2017 and incorporated by reference herein)
4.1		Form of Common Stock Purchase Warrant (filed as Exhibit 4.1 to our Form 8-K filed on October 19, 2017 and incorporated by reference herein)
4.2		Form of Wainwright Warrant (filed as Exhibit 4.2 to our Form 8-K filed on October 19, 2017 and incorporated by reference herein).
10.1		Form of Securities Purchase Agreement (filed as Exhibit 10.1 to our Form 8-K filed on October 19, 2017 and incorporated by reference herein).
31.1		Rule 13a-14(a) Certification of Chief Executive Officer*
31.2		Rule 13a-14(a) Certification of Principal Accounting Officer*
32.1		Section 1350 Certification of Chief Executive Officer*
32.2		Section 1350 Certification of Principal Accounting Officer*
101		The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, formatted in eXtensible Business Reporting Language (XBRL): (in) Unaudited Condensed Consolidated Balance Sheets at September 30, 2017 and December 31, 2016, (ii) Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2017 and 2016, (iii) Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.*

* Filed Herewith

EXHIBIT INDEX

1.1		Engagement Letter, dated as of October 12, 2017, by and between CASI Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (filed as Exhibit 1.1 to our Form 8-K filed on October 19, 2017 and incorporated by reference herein)
4.1		Form of Common Stock Purchase Warrant (filed as Exhibit 4.1 to our Form 8-K filed on October 19, 2017 and incorporated by reference herein)
4.2		Form of Wainwright Warrant (filed as Exhibit 4.2 to our Form 8-K filed on October 19, 2017 and incorporated by reference herein).
10.1		Form of Securities Purchase Agreement (filed as Exhibit 10.1 to our Form 8-K filed on October 19, 2017 and incorporated by reference herein).
31.1		Rule 13a-14(a) Certification of Chief Executive Officer*
31.2		Rule 13a-14(a) Certification of Principal Accounting Officer*
32.1		Section 1350 Certification of Chief Executive Officer*
32.2		Section 1350 Certification of Principal Accounting Officer*
101		The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, formatted in eXtensible Business Reporting Language (XBRL): (in) Unaudited Condensed Consolidated Balance Sheets at September 30, 2017 and December 31, 2016, (ii) Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2017 and 2016, (iii) Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.*

* Filed Herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CASI PHARMACEUTICALS, INC.
	(Registrant)

Date: November 14, 2017	/s/ Ken K. Ren
	Ken K. Ren
	Chief Executive Officer

Date: November 14, 2017	/s/ Sara B. Capitelli
	Sara B. Capitelli
	Principal Accounting Officer

EX-31.1 2 tv478651_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Ken K. Ren, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CASI Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2017

/s/ Ken K. Ren
Ken K. Ren
Chief Executive Officer

EX-31.2 3 tv478651_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL ACCOUNTING OFFICER

I, Sara B. Capitelli, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CASI Pharmaceuticals, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2017

/s/ Sara B. Capitelli
Sara B. Capitelli
Principal Accounting Officer

EX-32.1 4 tv478651_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION BY CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ken K. Ren, as Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

Date: November 14, 2017	/s/ Ken K. Ren
	Ken K. Ren
	Chief Executive Officer

EX-32.2 5 tv478651_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION BY PRINCIPAL ACCOUNTING OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sara B. Capitelli, as Principal Accounting Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

Date: November 14, 2017	/s/ Sara B. Capitelli
	Sara B. Capitelli
	Principal Accounting Officer

EX-101.INS 6 casi-20170930.xml XBRL INSTANCE DOCUMENT 0000895051 2016-01-01 2016-09-30 0000895051 2017-01-01 2017-09-30 0000895051 2016-07-01 2016-09-30 0000895051 2017-07-01 2017-09-30 0000895051 2017-09-30 0000895051 2017-11-06 0000895051 2016-12-31 0000895051 2015-12-31 0000895051 2016-09-30 0000895051 casi:CasiChinaMember 2017-09-30 0000895051 casi:SpectrumPharmaceuticalsMember 2016-03-17 0000895051 casi:SpectrumPharmaceuticalsMember 2016-03-01 2016-03-17 0000895051 us-gaap:FairValueInputsLevel1Member 2017-09-30 0000895051 us-gaap:FairValueInputsLevel2Member 2017-09-30 0000895051 us-gaap:FairValueInputsLevel3Member 2017-09-30 0000895051 us-gaap:FairValueInputsLevel1Member 2016-12-31 0000895051 us-gaap:FairValueInputsLevel2Member 2016-12-31 0000895051 us-gaap:FairValueInputsLevel3Member 2016-12-31 0000895051 casi:LongTermIncentivePlan2011Member us-gaap:MinimumMember 2017-09-30 0000895051 casi:LongTermIncentivePlan2011Member us-gaap:MaximumMember 2017-09-30 0000895051 casi:LongTermIncentivePlan2011Member 2017-09-30 0000895051 casi:LongTermIncentivePlan2011Member us-gaap:MinimumMember 2017-01-01 2017-09-30 0000895051 casi:LongTermIncentivePlan2011Member us-gaap:MaximumMember 2017-01-01 2017-09-30 0000895051 casi:BoardStaffOfficersAndEmployeesMember 2017-01-01 2017-09-30 0000895051 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0000895051 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0000895051 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0000895051 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-09-30 0000895051 casi:SpectrumMember 2017-01-01 2017-09-30 0000895051 casi:CrownBiosciencesIncMember 2016-01-01 2016-09-30 0000895051 us-gaap:FairValueInputsLevel3Member 2017-01-01 2017-09-30 0000895051 casi:InitialAndSecondClosingMember us-gaap:SubsequentEventMember 2017-10-01 2017-10-31 0000895051 casi:FinalClosingMember us-gaap:ScenarioForecastMember 2017-11-01 2017-11-30 0000895051 casi:SecuritiesPurchaseAgreementsMember us-gaap:SubsequentEventMember 2017-10-31 0000895051 casi:SecuritiesPurchaseAgreementsMember us-gaap:SubsequentEventMember 2017-10-01 2017-10-31 0000895051 us-gaap:PerformanceSharesMember 2016-01-01 2016-09-30 0000895051 us-gaap:PerformanceSharesMember 2017-01-01 2017-09-30 0000895051 us-gaap:SubsequentEventMember casi:SecuritiesPurchaseAgreementsMember casi:AgentWarrantsMember 2017-10-31 0000895051 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0000895051 us-gaap:WarrantMember 2017-01-01 2017-09-30 0000895051 casi:SecuritiesPurchaseAgreementsMember us-gaap:SubsequentEventMember casi:AgentWarrantsMember 2017-10-01 2017-10-31 0000895051 us-gaap:SubsequentEventMember 2017-10-01 2017-10-31 0000895051 casi:InvestorsMember 2016-01-01 2016-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2017-09-30 2017 Q3 CASI Pharmaceuticals, Inc. 0000895051 --12-31 Smaller Reporting Company CASI 65066564

27092928

441818

355891

22081886

27448819

566020

229591

68244

34485

22716150

27712895

1203965

470663323

470147086

8034244

-447654114

-441931827

15577725

20783775

22716150

27712895

7138425

6929120

4134931

4122266

1064626

302644

250950

3003494

1315576

21640068

602760

1496885

1491278

3747683

3395362

1961463

3356804

-5722287

-6779728

-0.10

-0.15

60196574

44132599

12665

4422

-23140

-476

970989

1013929

625878

676927

-1613523

-1693492

-0.03

60196574

49227983

16110

-2978

-5614

-546

69420

47963

516237

2201401

119686

-40840

139339

34793

51694

-7486

-5047011

-4449241

405849

159244

-405849

-798

-5452860

19006215

5131114

24137329

5607

21015

12461

158446

72087

17254341

23456254

3232502

3800000

5607

21015

1500000

0.005

136000

4134931

4122266

12665

11230000

14230000

12242004

0.86

13.75

2725000

2355358

578626

1622775

225342

290895

0.05 0.01

0.73

0.75

9535306

3699500

992802

12242004

8330511

1.57

1.04

1.64

1.41

1.59

3100000

477000

28648

1.00

5000000

0.01

170000000

60276119

79545

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 99.98%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="99%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Basis of Presentation</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The accompanying condensed consolidated financial statements include the accounts of CASI Pharmaceuticals, Inc. and its subsidiaries (“CASI” or “the Company”), Miikana Therapeutics, Inc. (“Miikana”) and CASI Pharmaceuticals (Beijing) Co., Ltd. (“CASI China”). The Company previously operated under a different name prior to restructuring its business in 2012 in connection with an investment led by one of the Company’s largest stockholders. CASI China is a non-stock Chinese entity with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of its interest owned by CASI. CASI China received approval for a business license from the Beijing Industry and Commercial Administration in August 2012 and has operating facilities in Beijing. All inter-company balances and transactions have been eliminated in consolidation.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, such condensed consolidated financial statements do not include all of the information and disclosures required by U.S. generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The accompanying December 31, 2016 financial information was derived from the Company’s audited financial statements in the Annual Report on Form 10-K for the year ended December 31, 2016. Operating results for the three and nine month periods ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in its Form 10-K for the year ended December 31, 2016.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Liquidity Risks and Management’s Plans</font></u></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Since inception, the Company has incurred significant losses from operations and <font style="COLOR: black">has incurred an accumulated deficit of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">447.7</font> million.  </font> The Company restructured its business in 2012 in connection with an investment led by one of the Company’s largest stockholders, followed by implementation of a name change to reflect its core mission and business strategy. The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical activities. In 2016, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28.1</font> million from strategic financings (“2016 Strategic Financings”). In October 2017, the Company entered into securities purchase agreements for an approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">23.8</font> million strategic financing. The Company held its initial closing on October 17, 2017 and second closing on October 23, 2017 and received approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.6</font> million (collectively, the “Closings”) (see Note 5). The Company expects to close on the remaining $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.2</font> million (“Final Closing”) during November 2017. Net proceeds will be used to support the Company’s business development activities, advance the development of the Company’s pipeline, and for other general corporate purposes. As a result of the Closings and the 2016 Strategic Financings, the Company believes that it has sufficient resources to fund its operations for at least the twelve months subsequent to November 14, 2017. As of September 30, 2017, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.8</font> million of the Company’s cash balance was held by CASI China. The Company intends to continue to exercise tight controls over operating expenditures and will continue to pursue opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive capital raising arrangements in China to support the Company’s dual-country approach to drug development.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 107%; WIDTH: 99.98%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="99%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 2.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> License Arrangements</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company has certain product rights and perpetual exclusive licenses from Spectrum Pharmaceuticals, Inc. and certain of its affiliates (together referred to as “Spectrum”) to develop and commercialize the following commercial oncology drugs and drug candidates in the greater China region (which includes China, Taiwan, Hong Kong and Macau) (the “Territories”):</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> EVOMELA<sup style="font-style:normal">®</sup> (melphalan) for Injection (“Evomela”);</font></div> </td> </tr> </table> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> MARQIBO<sup style="font-style:normal">®</sup> (vinCRIStine sulfate LIPOSOME injection) (“Marqibo”); and</font></div> </td> </tr> </table> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> ZEVALIN<sup style="font-style:normal">®</sup> (ibritumomab tiuxetan) (“Zevalin”).</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> CASI is responsible for developing and commercializing these three drugs in the Territories, including the submission of import drug registration applications and conducting confirmatory clinical trials as needed.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company is in various stages of the regulatory and development process to obtain marketing approval for EVOMELA<sup style="font-style:normal">®</sup>, MARQIBO<sup style="font-style:normal">®</sup>, and ZEVALIN<sup style="font-style:normal">®</sup> in its territorial region, with ZEVALIN<sup style="font-style:normal">®</sup> commercially available in Hong Kong. In January 2016, the China Food and Drug Administration (CFDA) accepted for review the Company’s import drug registration application for MARQIBO<sup style="font-style:normal">®</sup> and currently is in the quality testing phase of the regulatory process. On March 10, 2016, Spectrum received notification from the U.S. Food and Drug Administration (FDA) of the grant of approval of its New Drug Application (NDA) for EVOMELA<sup style="font-style:normal">®</sup> primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. In December 2016, the CFDA accepted for review the Company’s import drug registration application for EVOMELA<sup style="font-style:normal">®</sup> and in 2017 has granted priority review of the import drug registration clinical trial application (CTA), which currently is in the quality testing phase of the regulatory process. The CFDA filing and review of CASI’s ZEVALIN<sup style="font-style:normal">®</sup> import drug CTA is in process. The ZEVALIN<sup style="font-style:normal">®</sup> antibody kit and the radioactive Yttrium-90 component of the CTA require separate submissions to the CFDA, of which the first part is currently under review and the latter part is in the submission process.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 107%; WIDTH: 99.98%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="99%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 10.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">New Accounting Pronouncements</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company has implemented all new accounting pronouncements that are in effect and that may impact the Company’s condensed consolidated financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“<font style="COLOR: black">ASU”)</font> 2016-01, <i>Financial InstrumentsOverall: Recognition and Measurement of Financial Assets and Financial Liabilities</i>. <font style="COLOR: black"> The accounting standard primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments.  In addition, it includes a clarification related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2017. Early adoption is permitted for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company does not expect that the adoption of ASU 2016-01 will have a material impact on the consolidated financial statements.</font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 25.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; COLOR: black; FONT-SIZE: 10pt"> In February 2016, the FASB issued ASU 2016-02, <i>Leases (Topic 842)</i>. ASU 2016-02 supersedes existing lease guidance, including Accounting Standards Codification (ASC) 840 - <i> Leases</i>. Among other things, the new standard requires recognition of a right-of-use asset and liability for future lease payments for contracts that meet the definition of a lease.</font> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. <font style="COLOR: black">The standard must be applied using a modified retrospective approach.</font> The Company is currently evaluating the effect that the adoption of this ASU will have on its consolidated financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 25.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2017, the FASB issued ASU 2017-09,  <i>Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting.</i> ASU 2017-09 provides clarification on when modification accounting should be used for changes to the terms or conditions of a share-based payment award. This ASU does not change the accounting for modifications but clarifies that modification accounting guidance should only be applied if there is a change to the value, vesting conditions, or award classification and would not be required if the changes are considered non-substantive. <font style="COLOR: black">The Company is evaluating the impact of ASU 2017-09</font>.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 25.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company’s financial position, results of operations or cash flows.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 107%; WIDTH: 99.98%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="99%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 4.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Fair Value Measurements</font></strong></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Level 1, defined as observable inputs such as quoted prices in active markets for identical assets;</font></div> </td> </tr> </table> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Level 2, defined as observable inputs other than Level 1 prices such as quoted prices for similar assets; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</font></div> </td> </tr> </table> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company performs a detailed analysis of its assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair values are based on period-end statements supplied by the various banks and brokers that held the majority of the Company’s funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, and other current assets and liabilities) approximates their carrying values because of their short-term nature.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:</font></u></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As partial consideration for the acquisition from Spectrum, the Company issued certain contingent rights (“Contingent Rights”) to purchase additional shares of its common stock, which Contingent Rights expire upon the occurrence of certain events. The Contingent Rights issued to Spectrum in connection with the license arrangements (see Note 2) are considered derivative liabilities and were recorded initially at their estimated fair value, and are marked to market each reporting period until settlement. The fair value of the Contingent Rights was measured using Level 3 unobservable inputs; the unobservable inputs include estimates of the Company’s future capital requirements, and the timing, probability, size and characteristics of those capital raises, among other inputs. Generally, if the estimates of the size and probability of the Company’s future capital requirements increase, the fair value of the Contingent Rights will also increase.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table presents the Company’s financial liabilities accounted for at fair value on a recurring basis as of September 30, 2017 and December 31, 2016 by level within the fair value hierarchy:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%" colspan="11"> <div>As of September 30, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Liabilities - Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,134,931</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,134,931</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%" colspan="11"> <div>As of December 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Liabilities - Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,122,266</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,122,266</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table presents the changes in the Company’s financial liabilities accounted for at fair value on a recurring basis using Level 3 unobservable inputs:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>4,122,266</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Change in fair value of Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>12,665</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="54%"> <div>Balance at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>4,134,931</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As a result of the Closings (see Note 5), the Company has recorded a reduction to the Contingent Rights derivative liability and an increase to additional paid-in capital of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,762,979</font></font></font> in October 2017 which will be reflected in the Company’s December 31, 2017 consolidated financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:</font></u></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The promissory note issued to Spectrum in connection with the license arrangements (see Notes 2 and 3) was initially recorded at its fair value using Level 3 unobservable inputs including primarily the Company’s estimated incremental borrowing rate as provided by a commercial lending institution.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:</font></u></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company does not have any non-financial assets and liabilities that are measured at fair value on a recurring basis.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:</font></u></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company measures its long-lived assets, including property and equipment, at fair value on a non-recurring basis. These assets are recognized at fair value when they are deemed to be impaired. No such fair value impairment was recognized for the nine months ended September 30, 2017 and 2016.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following table presents the Company’s financial liabilities accounted for at fair value on a recurring basis as of September 30, 2017 and December 31, 2016 by level within the fair value hierarchy:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%" colspan="11"> <div>As of September 30, 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Liabilities - Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,134,931</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,134,931</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%" colspan="11"> <div>As of December 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Liabilities - Contingent Rights</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,122,266</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>4,122,266</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 99.98%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="99%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 7.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Share-Based Compensation</font></strong></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company has adopted incentive and nonqualified stock option plans for executive, scientific and administrative personnel of the Company as well as outside directors and consultants. In June 2017, the Company’s shareholders approved an amendment to the 2011 Long-Term Incentive Plan, increasing the number of shares reserved for issuance from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,230,000</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14,230,000</font> shares of common stock to be available for grants and awards. <font style="COLOR: black">As of September 30, 2017, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,242,004</font> shares issuable under options previously granted and currently outstanding, with exercise prices ranging from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.86</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13.75</font></font>. In 2017, the Company awarded options to employees, covering up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,725,000</font> shares, in which vesting is subject to achievement of certain performance milestones. Options granted under the plans generally vest over periods varying from immediately to one to three years, are not transferable and generally expire ten years from the date of grant. As of September 30, 2017, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,355,358</font> shares remained available for grant under the Company’s 2011 Long-Term Incentive Plan.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company records compensation expense associated with stock options and other equity-based compensation in accordance with provisions of authoritative guidance. Compensation costs are recognized over the requisite service period, which is generally the option vesting term of up to three years. <font style="COLOR: #252525">Awards with</font> performance conditions will be expensed if it is probable that the performance condition will be achieved. For the nine months ended September 30, 2017 and 2016, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,500</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,100</font>, respectively was expensed for share awards with performance conditions that became probable during that period.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company’s net loss for the nine months ended September 30, 2017 and 2016 includes non-cash compensation expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">516,237</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,201,401</font>, respectively, related to the Company’s share-based compensation awards. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine Month Period Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>225,342</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>578,626</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>290,895</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,622,775</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Share-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>516,237</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,201,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Net share-based compensation expense, per common share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.05</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of stock options granted to employees. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Following are the weighted-average assumptions used in valuing the stock options granted during the nine-month periods ended September 30, 2017 and 2016:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine Month Period Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>78.92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>83.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.97</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Expected term of option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.34 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.41 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Forfeiture rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%*</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Expected dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">* - In 2016, authoritative guidance required forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the nine-month period ended September 30, 2016, forfeitures were estimated at 3%.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The weighted average fair value of stock options granted during the nine-month periods ended September 30, 2017 and 2016 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.73</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font>, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the Company’s stock option plans and of changes in options outstanding under the plans for the nine months ended September 30, 2017 is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Outstanding at January 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9,535,306</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,699,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(992,802)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Outstanding at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>12,242,004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.41</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Exercisable at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>8,330,511</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">There were no option exercises during the nine months ended September 30, 2017 or 2016.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine Month Period Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>225,342</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>578,626</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>290,895</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,622,775</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Share-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>516,237</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,201,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Net share-based compensation expense, per common share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.05</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Following are the weighted-average assumptions used in valuing the stock options granted during the nine-month periods ended September 30, 2017 and 2016:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine Month Period Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>78.92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>83.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.97</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Expected term of option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.34 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.41 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Forfeiture rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%*</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Expected dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">* - In 2016, authoritative guidance required forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the nine-month period ended September 30, 2016, forfeitures were estimated at 3%.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">A summary of the Company’s stock option plans and of changes in options outstanding under the plans for the nine months ended September 30, 2017 is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Outstanding at January 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9,535,306</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,699,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(992,802)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Outstanding at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>12,242,004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.41</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Exercisable at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>8,330,511</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 107%; WIDTH: 99.98%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="99%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 5.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Stockholders’ Equity</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Securities Purchase Agreements</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On October 13, 2017, the Company entered into securities purchase agreements (the “Securities Purchase Agreements”) with certain institutional investors, accredited investors and current stockholders (collectively, the “Purchasers”) pursuant to which the Company agreed to sell <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,951,865</font> shares of its common stock and warrants exercisable for up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,590,373</font> shares of its common stock (exclusive of the Agent Warrants described below) in a registered direct offering (the “Offering”) for gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">23,855,595</font>. The shares and warrants are being sold together, consisting of one share of common stock and a warrant to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.20</font> shares of common stock for each share of common stock purchased, at a combined offering price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.00</font>. The warrants will be exercisable beginning on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">April 17, 2018</font> and will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">April 17, 2020</font>. The warrants have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.75</font> per share.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company held its initial closing on October 17, 2017 and second closing on October 23, 2017 (collectively, the “Closings”) and received approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.6</font> million and yielded approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.3</font> million after offering expenses. The Closings resulted in the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,869,990</font> shares of common stock. The Company expects to close on the remaining $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.2</font> million in November 2017, <font style="COLOR: black">subject to satisfaction of customary closing conditions.</font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In connection with the Offering, the Company issued to its placement agent or its designees warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 48,133</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.75</font> per share of common stock (the “Agent Warrants”), representing the number of warrants equal to an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4</font>% of the number of shares sold to investors placed by the placement agent in the Offering, excluding investments made by certain China-focused investors that were placed by the Company. The Agent Warrants will become exercisable on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">April 17, 2018</font> and will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">April 17, 2019</font>.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.7892

0.8303

0.0197

0.0131

0 0.0300

0.00

P6Y4M2D

P5Y4M28D

1596867

1690856

5709146

6752166

0 6274000

14600000

9200000

7951865

1590373

23855595

0.20

3.00

3.75

2020-04-17

2018-04-17

10100

516237

2201401

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 107%; WIDTH: 99.98%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="99%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 6.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Net Loss Per Share</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Net loss per share (basic and diluted) was computed by dividing net loss attributable to common shareholders by the weighted average number of shares of common stock outstanding. Outstanding stock options and warrants totaling 12,242,004 and 4,686,760 as of September 30, 2017, respectively, were anti-dilutive and, therefore, were not included in the computation of weighted average shares used in computing diluted loss per share.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

14300000

4869990

48133

12242004

4686760

3.75

2018-04-17

2019-04-17 2762979

28100000

0.04

30500

In 2016, authoritative guidance required forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the nine-month period ended September 30, 2016, forfeitures were estimated at 3%.

EX-101.SCH 7 casi-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - License Arrangements link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Note Payable link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Share-Based Compensation link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - New Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Basis of Presentation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Note Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Fair Value Measurements (Details 1) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Fair Value Measurements (Details Textual) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Net Loss Per Share (Details Textual) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Share-Based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Share-Based Compensation (Details 2) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Share-Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 casi-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 casi-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 casi-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Shedule of Description of Business and Basis of Presentation [Table] Legal Entity [Axis] Entity [Domain] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Forecast [Member] Class of Stock [Domain] Stock Issued [Axis] Retained Earnings (Accumulated Deficit) Accumulated deficit Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] General and Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation, Total Share-based compensation expense Stock-based compensation expense Net Share Based Compensation Expense Per Common Share Abstract Net share-based compensation expense, per common share: Share Based Compensation Expenses Basic and Diluted Per Share Basic and diluted (in dollars per share) The amount of share-based compensation expenses per each share of common stock or unit outstanding during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term of option Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate Forfeiture rate The forfeiture Rate assumption that is used in valuing an option on its own shares. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Type of Deferred Compensation [Axis] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Outstanding - Number of Options, Beginning Balance Outstanding - Number of Options, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross Granted - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period Exercised - Number of Options Issuance of common stock from exercise of contingent purchase right (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Expirations In Period Expired - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Forfeited - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Exercisable - Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding - Weighted Average Exercise Price, Beginning balance Outstanding - Weighted Average Exercise Price, Ending Balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited - Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable - Weighted Average Exercise Price Plan Name [Axis] Plan Name [Domain] Long Term Incentive Plan2011 [Member] Range [Axis] Range [Domain] Minimum [Member] Maximum [Member] Title of Individual [Axis] Relationship to Entity [Domain] Equity Components [Axis] Equity Component [Domain] Award Type [Axis] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Allocated Share-based Compensation Expense Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of Exercise Prices Lower Range Limit Income Tax Contingency [Table] Equity Award [Domain] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Unrecognized Tax Benefits, Beginning Balance Unrecognized Tax Benefits Unrecognized tax benefits balance at January 1 Unrecognized tax benefits balance at December 31 Statement Of Financial Position [Abstract] Statement [Table] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Prepaid Expense and Other Assets, Current Prepaid expenses and other Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net Other Assets, Noncurrent Other assets Assets, Total Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued liabilities Notes Payable, Noncurrent Note payable, net of discount Notes Payable, Current Note payable, net of discount Derivative Liability, Noncurrent Contingent rights derivative liability Preferred Stock, Value, Issued Convertible preferred stock, $1.00 par value; 5,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2017 and December 31, 2016 Common Stock, Value, Issued Common stock, $.01 par value: 170,000,000 shares authorized; 60,276,119 shares issued at September 30, 2017 and December 31, 2016 Additional Paid in Capital, Total Additional paid-in capital Treasury Stock, Value Treasury stock, at cost: 79,545 shares held Stockholders Equity Attributable to Parent, Total Total stockholders' equity Balance Balance Liabilities Total liabilities Preferred Stock, Par or Stated Value Per Share Convertible preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Convertible preferred stock, shares authorized Preferred Stock, Shares Issued Convertible preferred stock, shares issued Preferred Stock, Shares Outstanding Convertible preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Income Statement [Abstract] Revenues [Abstract] Revenues: Costs and Expenses [Abstract] Costs and expenses: Research and Development Expense, Total Research and development General and Administrative Expense, Total General and administrative Interest Income (Expense), Net, Total Interest expense, net Increase (Decrease) in Derivative Liabilities Change in fair value of contingent rights Net Income (Loss) Attributable to Parent, Total Net loss Net loss Earnings Per Share, Basic and Diluted, Total Net loss per share (basic and diluted) (in dollars per share) Statement Of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Gain on disposal of assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Accrued Liabilities, Total Accrued liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from Sale of Property, Plant, and Equipment Proceeds from sale of furniture and equipment Payments to Acquire Property, Plant, and Equipment, Total Purchases of furniture and equipment Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Cash and Cash Equivalents, Period Increase (Decrease), Total Net (decrease) increase in cash and cash equivalents Basis Of Accounting [Text Block] Basis of Accounting [Text Block] Commitments and Contingencies Commitments and contingencies Paid-in-Kind Interest Non-cash interest New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Research and Development [Abstract] Research, Development, and Computer Software Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Schedule of Notes payable [Table] Related Party [Axis] Related Party [Domain] Subsequent Event Type [Axis] Spectrum Pharmaceuticals [Member] Amortization of Debt Discount (Premium) Debt Instrument, Interest Rate, Stated Percentage Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value December 31, 2016 Balance at September 30, 2017 Liabilities - Contingent Rights Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total Change in fair value of Contingent Rights Stockholders Equity Attributable To Parent [Abstract] Stockholders' equity: Liabilities and Equity, Total Total liabilities and stockholders' equity Weighted Average Number Of Shares Outstanding, Basic and Diluted Weighted average number of common shares outstanding (basic and diluted) (in shares) Increase (Decrease) In Operating Capital [Abstract] Changes in operating assets and liabilities: Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Share Based Compensation Arrangement By Share Based Payment Award Options Granted Subject To Achievement Gross number of share options (or share units) of common stock to be available for grants and awards issuance subject to achievement. Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Range of Exercise Prices Upper Range Limit Percentage Of Ownership Interest In Non Stock Subsidiary Percentage of ownership interest held by the parent entity in the non stock subsidiary. Assets, Current, Total Total current assets Treasury Stock, Shares Treasury stock, shares held Costs and Expenses, Total Costs and expenses Revenue, Net Product sales Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Geographical [Axis] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash financing activity: Liabilities, Current, Total Total current liabilities Crown Biosciences, Inc [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Maximum Stock To Be Issued Maximum stock to be issued. Stock Issued [Domain] Securities Purchase Agreements [Abstract] Stock To Be Issued, Shares Stock to be issued in shares. Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Subsequent Event Type [Domain] Cash Flow, Noncash Investing Activities Disclosure [Abstract] Non-cash investing activity: Proceeds from Issuance of Common Stock Proceeds from sale of common stock Sale of Stock [Axis] Subsequent Event [Member] Income Tax Contingency [Line Items] Geographical [Domain] EX-101.PRE 11 casi-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2017	Nov. 06, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Entity Registrant Name	CASI Pharmaceuticals, Inc.
Entity Central Index Key	0000895051
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CASI
Entity Common Stock, Shares Outstanding		65,066,564

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 21,640,068	$ 27,092,928
Prepaid expenses and other	441,818	355,891
Total current assets	22,081,886	27,448,819
Property and equipment, net	566,020	229,591
Other assets	68,244	34,485
Total assets	22,716,150	27,712,895
Current liabilities:
Accounts payable	1,203,965	1,064,626
Accrued liabilities	302,644	250,950
Note payable, net of discount	1,496,885	0
Total current liabilities	3,003,494	1,315,576
Note payable, net of discount	0	1,491,278
Contingent rights derivative liability	4,134,931	4,122,266
Total liabilities	7,138,425	6,929,120
Commitments and contingencies
Stockholders' equity:
Convertible preferred stock, $1.00 par value; 5,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2017 and December 31, 2016	0	0
Common stock, $.01 par value: 170,000,000 shares authorized; 60,276,119 shares issued at September 30, 2017 and December 31, 2016	602,760	602,760
Additional paid-in capital	470,663,323	470,147,086
Treasury stock, at cost: 79,545 shares held	(8,034,244)	(8,034,244)
Accumulated deficit	(447,654,114)	(441,931,827)
Total stockholders' equity	15,577,725	20,783,775
Total liabilities and stockholders' equity	$ 22,716,150	$ 27,712,895

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets [Parenthetical] - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Convertible preferred stock, par value (in dollars per share)	$ 1.00	$ 1.00
Convertible preferred stock, shares authorized	5,000,000	5,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	60,276,119	60,276,119
Treasury stock, shares held	79,545	79,545

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Product sales	$ 0	$ 0	$ 0	$ 0
Costs and expenses:
Research and development	970,989	1,013,929	3,747,683	3,395,362
General and administrative	625,878	676,927	1,961,463	3,356,804
Costs and expenses	1,596,867	1,690,856	5,709,146	6,752,166
Interest expense, net	546	5,614	476	23,140
Change in fair value of contingent rights	16,110	(2,978)	12,665	4,422
Net loss	$ (1,613,523)	$ (1,693,492)	$ (5,722,287)	$ (6,779,728)
Net loss per share (basic and diluted) (in dollars per share)	$ (0.03)	$ (0.03)	$ (0.10)	$ (0.15)
Weighted average number of common shares outstanding (basic and diluted) (in shares)	60,196,574	49,227,983	60,196,574	44,132,599

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (5,722,287)	$ (6,779,728)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	69,420	47,963
Gain on disposal of assets	0	(12,461)
Stock-based compensation expense	516,237	2,201,401
Non-cash interest	5,607	21,015
Change in fair value of contingent rights	12,665	4,422
Changes in operating assets and liabilities:
Prepaid expenses and other	(119,686)	40,840
Accounts payable	139,339	34,793
Accrued liabilities	51,694	(7,486)
Net cash used in operating activities	(5,047,011)	(4,449,241)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of furniture and equipment	0	158,446
Purchases of furniture and equipment	(405,849)	(159,244)
Net cash used in investing activities	(405,849)	(798)
CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuance costs	0	(72,087)
Proceeds from sale of common stock	0	17,254,341
Proceeds from sale of common stock to be issued	0	6,274,000
Net cash provided by financing activities	0	23,456,254
Net (decrease) increase in cash and cash equivalents	(5,452,860)	19,006,215
Cash and cash equivalents at beginning of period	27,092,928	5,131,114
Cash and cash equivalents at end of period	21,640,068	24,137,329
Non-cash financing activity:
Partial settlement of contingent rights derivative	$ 0	$ 3,232,502

XML 17 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Accounting [Text Block]

1.	Basis of Presentation

Liquidity Risks and Management’s Plans

XML 18 R7.htm IDEA: XBRL DOCUMENT

License Arrangements

9 Months Ended

Sep. 30, 2017

Research and Development [Abstract]

Research, Development, and Computer Software Disclosure [Text Block]

2.	License Arrangements

⋅

EVOMELA^® (melphalan) for Injection (“Evomela”);

⋅

MARQIBO^® (vinCRIStine sulfate LIPOSOME injection) (“Marqibo”); and

⋅

ZEVALIN^® (ibritumomab tiuxetan) (“Zevalin”).

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note Payable

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

3.	Note Payable

XML 20 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

4.	Fair Value Measurements

⋅

Level 1, defined as observable inputs such as quoted prices in active markets for identical assets;

⋅

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:

	As of September 30, 2017
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	4,134,931	$	4,134,931

	As of December 31, 2016
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	4,122,266	$	4,122,266

The following table presents the changes in the Company’s financial liabilities accounted for at fair value on a recurring basis using Level 3 unobservable inputs:

December 31, 2016	$	4,122,266
Change in fair value of Contingent Rights		12,665
Balance at September 30, 2017	$	4,134,931

Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:

Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis:

The Company does not have any non-financial assets and liabilities that are measured at fair value on a recurring basis.

Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis:

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

5.	Stockholders’ Equity

Securities Purchase Agreements

XML 22 R11.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

6.	Net Loss Per Share

XML 23 R12.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

7.	Share-Based Compensation

	Nine Month Period Ended
	September 30,
	2017		2016
Research and development	$	225,342	$	578,626
General and administrative		290,895		1,622,775
Share-based compensation expense	$	516,237	$	2,201,401
Net share-based compensation expense, per common share:
Basic and diluted	$	0.01	$	0.05

Following are the weighted-average assumptions used in valuing the stock options granted during the nine-month periods ended September 30, 2017 and 2016:

	Nine Month Period Ended
	September 30,
	2017			2016
Expected volatility		78.92	%		83.03	%
Risk-free interest rate		1.97	%		1.31	%
Expected term of option		6.34 years			5.41 years
Forfeiture rate		-			3.00	%*
Expected dividend yield		0.00	%		0.00	%

The weighted average fair value of stock options granted during the nine-month periods ended September 30, 2017 and 2016 were $0.73 and $0.75, respectively.

A summary of the Company’s stock option plans and of changes in options outstanding under the plans for the nine months ended September 30, 2017 is as follows:

			Weighted
			Average
	Number of		Exercise
	Options		Price
Outstanding at January 1, 2017		9,535,306	$	1.57
Granted		3,699,500	$	1.04
Exercised		-	$	-
Expired		(992,802)	$	1.64
Forfeited		-	$	-
Outstanding at September 30, 2017		12,242,004	$	1.41
Exercisable at September 30, 2017		8,330,511	$	1.59

There were no option exercises during the nine months ended September 30, 2017 or 2016.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2017

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

8.	Income Taxes

XML 25 R14.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2017

9.	Related Party Transactions

XML 26 R15.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements

9 Months Ended

Sep. 30, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

10.

New Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact the Company’s condensed consolidated financial statements.

There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company’s financial position, results of operations or cash flows.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2017

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

	As of September 30, 2017
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	4,134,931	$	4,134,931

	As of December 31, 2016
	Level 1		Level 2		Level 3		Total

Liabilities - Contingent Rights	$	-	$	-	$	4,122,266	$	4,122,266

Fair Value, Inputs, Level 3 [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table presents the changes in the Company’s financial liabilities accounted for at fair value on a recurring basis using Level 3 unobservable inputs:

December 31, 2016	$	4,122,266
Change in fair value of Contingent Rights		12,665
Balance at September 30, 2017	$	4,134,931

XML 28 R17.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:

	Nine Month Period Ended
	September 30,
	2017		2016
Research and development	$	225,342	$	578,626
General and administrative		290,895		1,622,775
Share-based compensation expense	$	516,237	$	2,201,401
Net share-based compensation expense, per common share:
Basic and diluted	$	0.01	$	0.05

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Following are the weighted-average assumptions used in valuing the stock options granted during the nine-month periods ended September 30, 2017 and 2016:

	Nine Month Period Ended
	September 30,
	2017			2016
Expected volatility		78.92	%		83.03	%
Risk-free interest rate		1.97	%		1.31	%
Expected term of option		6.34 years			5.41 years
Forfeiture rate		-			3.00	%*
Expected dividend yield		0.00	%		0.00	%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the Company’s stock option plans and of changes in options outstanding under the plans for the nine months ended September 30, 2017 is as follows:

			Weighted
			Average
	Number of		Exercise
	Options		Price
Outstanding at January 1, 2017		9,535,306	$	1.57
Granted		3,699,500	$	1.04
Exercised		-	$	-
Expired		(992,802)	$	1.64
Forfeited		-	$	-
Outstanding at September 30, 2017		12,242,004	$	1.41
Exercisable at September 30, 2017		8,330,511	$	1.59

XML 29 R18.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details Textual) - USD ($)	1 Months Ended		9 Months Ended		12 Months Ended
Basis of Presentation (Details Textual) - USD ($)	Nov. 30, 2017	Oct. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Description of Business and Basis of Presentation [Line Items]
Retained Earnings (Accumulated Deficit)			$ (447,654,114)		$ (441,931,827)
Percentage Of Ownership Interest In Non Stock Subsidiary			100.00%
Proceeds from Issuance of Common Stock			$ 0	$ 17,254,341
Investors [Member]
Description of Business and Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock					$ 28,100,000
Subsequent Event [Member] \| Securities Purchase Agreements [Member]
Description of Business and Basis of Presentation [Line Items]
Maximum Stock To Be Issued		$ 23,855,595
Subsequent Event [Member] \| Initial and Second Closing [Member]
Description of Business and Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock		$ 14,600,000
Scenario, Forecast [Member] \| Final Closing [Member]
Description of Business and Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock	$ 9,200,000
CASI China [Member]
Description of Business and Basis of Presentation [Line Items]
Cash			$ 3,800,000

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note Payable (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
Note Payable (Details Textual) - USD ($)	Mar. 17, 2016	Sep. 30, 2017	Sep. 30, 2016
Notes Payable [Line Items]
Amortization of Debt Discount (Premium)		$ 5,607	$ 21,015
Spectrum Pharmaceuticals [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	0.50%
Debt Instrument Initial Discount Upon Issuance	$ 136,000
Debt Instrument, Face Amount	$ 1,500,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities - Contingent Rights	$ 4,134,931	$ 4,122,266
Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities - Contingent Rights	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities - Contingent Rights	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities - Contingent Rights	$ 4,134,931	$ 4,122,266

XML 32 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details 1)	9 Months Ended
Fair Value Measurements (Details 1)	Sep. 30, 2017 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
December 31, 2016	$ 4,122,266
Change in fair value of Contingent Rights	12,665
Balance at September 30, 2017	$ 4,134,931

XML 33 R22.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details Textual)	1 Months Ended
Fair Value Measurements (Details Textual)	Oct. 31, 2017 USD ($)
Subsequent Event [Member]
Adjustments to Additional Paid in Capital, Stock Issued	$ 2,762,979

XML 34 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended		9 Months Ended
Stockholders' Equity (Details Textual) - USD ($)	Nov. 30, 2017	Oct. 31, 2017	Sep. 30, 2017	Sep. 30, 2016
Proceeds from Issuance of Common Stock			$ 0	$ 17,254,341
Final Closing [Member] \| Scenario, Forecast [Member]
Proceeds from Issuance of Common Stock	$ 9,200,000
Securities Purchase Agreements [Member] \| Subsequent Event [Member]
Stock To Be Issued, Shares		7,951,865
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 3.75
Sale of Stock, Price Per Share		$ 3.00
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,590,373
Maximum Stock To Be Issued		$ 23,855,595
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		0.20
Class of Warrant or Right, Expiration Date		Apr. 17, 2020
Class of Warrant or Right, Date from which Warrants or Rights Exercisable		Apr. 17, 2018
Securities Purchase Agreements [Member] \| Subsequent Event [Member] \| Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 3.75
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		48,133
Class of Warrant or Right, Expiration Date		Apr. 17, 2019
Class of Warrant or Right, Date from which Warrants or Rights Exercisable		Apr. 17, 2018
Agent Warrants Percentage		4.00%
Initial and Second Closing [Member] \| Subsequent Event [Member]
Proceeds from Issuance of Common Stock		$ 14,600,000
Sale of Stock, Number of Shares Issued in Transaction		4,869,990
Net Proceeds From Issuance Of Common Stock		$ 14,300,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Details Textual)	9 Months Ended
Net Loss Per Share (Details Textual)	Sep. 30, 2017 shares
Warrant [Member]
Net loss per share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,686,760
Employee Stock Option [Member]
Net loss per share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,242,004

XML 36 R25.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details) - USD ($)	9 Months Ended
Share-Based Compensation (Details) - USD ($)	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 516,237	$ 2,201,401
Net share-based compensation expense, per common share:
Basic and diluted (in dollars per share)	$ 0.01	$ 0.05
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 225,342	$ 578,626
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 290,895	$ 1,622,775

XML 37 R26.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details 1)

9 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected volatility

78.92%

83.03%

Risk-free interest rate

1.97%

1.31%

Expected term of option

6 years 4 months 2 days

5 years 4 months 28 days

Forfeiture rate

0.00%

3.00%

^[1]

Expected dividend yield

0.00%

[1]	In 2016, authoritative guidance required forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the nine-month period ended September 30, 2016, forfeitures were estimated at 3%.

XML 38 R27.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details 2)	9 Months Ended
Share-Based Compensation (Details 2)	Sep. 30, 2017 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding - Number of Options, Beginning Balance \| shares	9,535,306
Granted - Number of Options \| shares	3,699,500
Exercised - Number of Options \| shares	0
Expired - Number of Options \| shares	(992,802)
Forfeited - Number of Options \| shares	0
Outstanding - Number of Options, Ending Balance \| shares	12,242,004
Exercisable - Number of Options \| shares	8,330,511
Outstanding - Weighted Average Exercise Price, Beginning balance \| $ / shares	$ 1.57
Granted - Weighted Average Exercise Price \| $ / shares	1.04
Exercised - Weighted Average Exercise Price \| $ / shares	0
Expired - Weighted Average Exercise Price \| $ / shares	1.64
Forfeited - Weighted Average Exercise Price \| $ / shares	0
Outstanding - Weighted Average Exercise Price, Ending Balance \| $ / shares	1.41
Exercisable - Weighted Average Exercise Price \| $ / shares	$ 1.59

XML 39 R28.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details Textual) - USD ($)	9 Months Ended
Share-Based Compensation (Details Textual) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.73	$ 0.75
Share-based Compensation, Total	$ 516,237	$ 2,201,401
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	12,242,004		9,535,306
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total	$ 516,237	2,201,401
Allocated Share-based Compensation Expense	$ 30,500	$ 10,100
Certain Board Members Officers And Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Granted Subject To Achievement	2,725,000
Long Term Incentive Plan2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	2,355,358
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	12,242,004
Long Term Incentive Plan2011 [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	11,230,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 0.86
Long Term Incentive Plan2011 [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	14,230,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 13.75

XML 40 R29.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Textual) $ in Millions	Dec. 31, 2016 USD ($)
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits	$ 3.1

XML 41 R30.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Research and Development Expense, Total	$ 970,989	$ 1,013,929	$ 3,747,683	$ 3,395,362
Crown Biosciences, Inc [Member]
Research and Development Expense, Total				$ 28,648
Spectrum [Member]
Research and Development Expense, Total			$ 477,000

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,U0;DL?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ S5!N2V;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " #-4&Y+[+L_%.X K @ $0 &1O8U!R;W!S+V-O M&ULS9+!3L,P#(9?!>7>NMD*2%&7"X@32$A, G&+'&^+:-HH,6KW]J1E MZX3@ 3C&_O/YL^0&@\(^TG/L T5VE*Y&WW9)8=B( W-0 D/Y$TJ'\C'L(!C_,GF!553?@B8TU;& "%F$A"MU85!C)(L+/GS&=H99!&K) M4\<)9"E!Z&EB.(YM Q? !&.*/GT7R"[$N?HG=NZ ."7'Y);4, SEL)YS>0<) M;T^/+_.ZA>L2FPXI_TI.\3'01IPGOZ[O[K5M(6621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( ,U0;DOJ%F)690( !0( 8 >&PO=V]R:W-H965T&UL?5;;CILP$/T5Q ^4U(2)XZ]J>[\):B.$YBGA5DP[S)SJ07IY< M*>NPD$MVB_C "+YH4M=&"( LZG#3AV6A]TZL+.A=M$U/3BS@]Z[#[/>!M'3< MA3!\WWAI;K50&U%9#/A&OA'Q?3@QN8IF*Y>F(SUO:!\P_A\A(DB:,2/ MAHQ\,0]4*&=*7]7B\V47 N41:4DEE DLAP)[*U[H^(E, :5A,$7_A3Q(*^'*$ZE1T9;K MWZ"ZGSV2T7.X^2E!$#V5F0AP, BT0<$9$TO8L M@'P"!^30T;\"1Q<1^P5B;P2QIL<+>N*G)UYZHNG)@IY:%^ B,K] ZA5('7IN M";B(C5\@\PID#GUK";@("/P*N5V(ZPFVY'/*CHO=>]<+$[M[P]TF_T7[CIEU\QNS4]#\Y4R)=> MO\=72@61#H$GZ4HM6_2\:,E5J&DNY\ST*;,0=)AZ<#3_$2C_ %!+ P04 M" #-4&Y+=3GL&:@# "\#P & 'AL+W=O4[D6B@_\9_C,2/Y&;6]U\;R_6=L&/LJC:;7CINNM#%+7'BRVS]F-]M97[ MY5PW9=:YR^8Y:J^-S4Y#4%E$&,;X=YCL]O4+UV15_:Q"=J7LLR: MGWM;U+=M".';C<_Y\Z7K;T2[S35[MO_8[LOUL7%7T3W+*2]MU>9U%33VO U_ M@X<#)GW H/B:VUL[.P_Z4I[J^GM_\==I&\:](UO88]>GR-SAU1YL4?29G(]_ MIZ3A?74Q9GI\&HZW*?];&!^ 4P#> T"^ M&R"F .$%1*.SH=3?LR[;;9KZ%C3CT[IF_4L!#\(U\]C?''HW_.:J;=W=UQW* M3?3:YYDD^U&"<\E2<6 4R5T2N?'O)I U@4.\F,=N/5P@AUG&**AG2.O(&VH^29#:0E&# ]T-E(DE,"KR;A'63 M4#>IYR8APR#&SHU1GA]&J*4T!E+>D6(=*>)(Q)XC109*E(K1DQVH##%-UOJC M63>:N@'/C2;#*(/2FRH'JA*N-RMSP;!>#/7B3;>]84K6H"#Q>\,(M08TZ8JC ME'64DMDI!!\/,<^8F-9$(!,3KX"Q2%7BLX81QDJJ-6+ "O> >DI\3T ?9XR* M/'5&ATF2_OH-?$^R7"_Q1$5*5)]*>Z2@=)]/K7PSO]8M'?$\ M1ECI42 H5OBI6"^S,K,P)7EI:4JM)G!E)8?C".8_3[_G^42U<\ M79'25?IT10K-#U)JE4@ XHO5@N.,F:V$E\YXQB)EK/2IA@Q 'VQ_PK$7*6NES;=(L5N[\LHA3\NNB:+:-ZO>UG[+F.:_:X*GNW(YLV#>= MZ[JS+FO\T66]N*WT_:*PYZX_U>Z\&?>3XT577Z>]V$[=_7-BP"@Y+- M0[#-F9DS@.RLH^R5EP#">JM)PW=V*42[18B?2J@QW] 6&GGG0EF-A9RR*^(M M WS6035!GN-$J,958^>97CNP/*,W0:H&#LSBM[K&[-\>".UVMFN_+[Q4UU*H M!91G+;["3Q"_V@.3,S1F.5TH(2!P$BH#EI<[%$"(2B0U_@XY[;&D"IR.W[-_T;W+7HZ80T')G^HL MRIV=V-89+OA&Q OMOL+03VA;0_/?X0Y$XLI$UCA1PO6_=;IQ0>LABU2I\5M_ MK1I][?H[43R$K0=X0X W!KC!PP!_"/"- -2;Z58_8X'SC-'.8OW+:K'Z)MRM M+Q_F22WJ9Z?OR6ZY7+WGH9.AN\HS(/L>\2:(-R>*%2(<$23KCQ+>JH2GXX.I MA&M(]$BLD48C!E$\(F8._JJ#OW0PVMSW2#BI$#KZ9Y@\YV8^P:I/L/3Q#9]@ M4<43,',)5AW#I$!@.X5.'1\3,(5IUB)8.H>'0(\FTPL8Q/X\GT,PD7C6) MER:181(O>G5C9_4;^0@Y/%D>NFAM('P)E1NFJ4+HT2 MPRA=%(K3,##>:O&,ZEW09*-3!\\/S*Y5PZTC%7+/U#O;A5(!,J.SD=:- M$P(7H8:Q'+-^Q^\G@K;#88;&$S7_#U!+ P04 " #-4&Y+"T:O8DL# # M# & 'AL+W=O5?52 M[Z74WFN1E_7,WVM]F 1!O=[+(JWOU4&6YI^MJHI4FV:U"^I#)=--:RKR@" 4 M!46:E?Y\VO8]5O.I.NH\*^5CY=7'HDBK?PN9J_/,Q_Y;QU.VV^NF(YA/#^E. M_I3ZU^&Q,JU@B++)"EG6F2J]2FYG_@.>K#!M#*WB=R;/]>C>:U">E7II&M\V M,Q\U&1V_28ZR=U_BI[(.9[/?UW>9*YD3>9F#'6*J_;7V]]K+4J^B@FE2)] M[:Y9V5[/??PWF]M >@,9#&;L6P;:&^B[(;QI"'M#^-D16&]@8(2@8V^+F:0Z MG4\K=?:J;CT2 MQ);@01&8\82LI6 DJ]_%"1?*A8W5)<<# G![/K$+K]D=,?V75@H Z=A(TR M%!R)&"S-I2W#"%-!@"ZQ=92'/(I!^5<.'16,7IMF[L3C-EX$\+@U3D18S&. MYY#Q2! .Z&P9%A$.X>):V3I*612C*Y,7.^EBFP[DLXCM?)B(8JA;.G210#$# MU4IL'3.+P0 "/EL7<4;PJ/H7?,+))VP^,"T+8><#!COG+(PI!<>=KPE3<8 MMN X@G#8VO'N#!UEA$(^IU+04!"(Z% R3@B).:1T*"/.!2?Q%5+G:_(!$YL4 M0]).$X_'0O?(POR4+''+,.1SJ]@5./?+%5,;CD X:C_AR.QUC(>0SU::&21< MP"T_^73,E2MFB"EA0@#28'3Z*F2U:X_"M;=6QU(W+\Y1[W#T]*VW.C.W);JN4E@8 W9O4]^9S8FCDT# #S$ M& 'AL+W=O?FJNMW3^GIJWRWEVVYZ2[MC8_CD95F0!C M*JGRHHZWZW'MI=VNFUM?%K5]::/N5E5Y^^_.ELU]$_/XQ\+7XGSIAX5DN[[F M9_N'[?^\OK3N*GEX.1:5K;NBJ:/6GC;Q,W_:@QD,1L1?A;UWB_-H2.6U:;X- M%[\>-S$;&-G2'OK!1>X.;W9ORW+PY'C\,SN-'S$'P^7Y#^]?QN1=,J]Y9_=- M^7=Q["^;.(NCHSWEM[+_VMQ_L7-":1S-V?]FWVSIX ,3%^/0E-WX&QUN7=]4 MLQ='IB'H_WZ1^M9C/: &8#>!BXV!\9B-E _#208_(3LS'5SWF?;]=M M!C\S9#=!8 'A#T3BG#\B M !5A!\@1A,D71!51H*7]QZCI#9*T%PTR45C M+E[1=AI%\7E@Q(J##+5)1A+),)',(Y*A,"E7(/R;C&$ C$L6H&-(.@;3,1X= M@^DHYI/!(.",!]J%,UH%&"*C?#(S9AF(@U*I1X> 20D0H!,0)8[Z/V,!#Z3H M/'- "8%_LV?,^Z;B1F7*3PD#) M2TZK'L>R)U*?D*0>""-]/ABVTG)1Q_=\:,WC*>*3<9]/B@.E3&K&N4^)0$HI M#4*MV*HF6G]XU@ ,[3%_K\"$A">9E*&BDQK(,] M&?/1/2<@*PULX>H]&5H+ 6MAYFLA8(E#9#"$:TBE"#U10 LA8"',_+T&L, A M.ABB0$O& K(,M H"5D'CO_P!EC?$!D- R%2Y^@3HT"((6 2-+X) B:!,(5.( M%49RXR8\"+T> "V"@-\G#?BL\*LB:&; ^/ONGD"F7'#.0Z6B=16PKAI?5P&+ M)G#EFD0A4@12\/1=U%[TV MO1MDQW'SU#2]=3S9)U?RB\V/CXO2GOKA5+OS=AK#IXN^N&:8<^;,>)P-UKWY%B"0=ZV,SVD;0G=@S)FF!%O,4X-KTB9Y4MK>I"U>1.=E?>;I/OZECYO^3;A&&D_.-N"M MIMG7U@9 )9L[7)\6']?L**A#-!_0=N.*C4ZPW?1ZV/R$B[]02P,$% @ MS5!N2TM6IO1QKENSY@M&M#"7F 'K;^IT&CAO&EJ9CL#HHP@ MK1A/DBNFA6QIGD;?T>0I]D[)%HZ&V%YK8=X.H'#(Z(:^.QYEW;C@8'G:B1I^ M@OO5'8VWV,Q22@VME=@2 U5&;S;[PR[$QX G"8-=G$FHY(3X'(SO94:3( @4 M%"XP"+^=X1:4"D1>QLO$2>>4 ;@\O[/?Q]I]+2=AX1;5;UFZ)J/7E)10B5ZY M1QR^P53/)253\3_@#,J'!R4^1X'*QI44O76H)Q8O18O7<9=MW(?QYNKK!%L' M\ G 9\!US,/&1%'YG7 B3PT.Q(R][T1XXLV>^]X4P1E;$>^\>.N]YWR3)"D[ M!Z(IYC#&\&7,',$\^YR"KZ4X\'_@?!V^756XC?#M!X7_R;];)=A%@MT' OZI MQ+68[:"GA-&NSB144 ;@^O[$_Q=I]+6=AX0'5+UFY-J=WE%10BT&Y9QP_ MPUS/-25S\5_A LJ'!R4^1XG*QI64@W6H9Q8O18O7:9==W,?IAG^:8=L /@/X M KB+>=B4*"I_%$X4F<&1F*GWO0A/O#MPWYLR.&,KXIT7;[WW4NR2-&.70#3' M'*<8OHY9(IAG7U+PK11'_A^<;\/WFPKW$;Y_I_!ZFR#=)$@C0?J.X.9#B5LQ MMQ^2L%5/-9@F3I,E)0Y=G.25=QG8>Q[?Y%_X-.W?A&ED9\D9G7_9V/\:T8&7 MDESY$6K]!UL,!;4+QUM_-M.838;#?OY!;/G&Q5]02P,$% @ S5!N2Z1= M]I*V 0 T@, !@ !X;"]W;W)KV$ *[Y0VRSIWW=L"*4I+[9G/.?,F?$X M'XU]<1V )Z]*:E?0SOO^R)BK.E#--XTQBKNT;0M<[T%7D>0DBQ+DCNF MN-"TS*/O;,O<#%X*#6=+W* 4M[]/(,U8T)2^.9Y$V_G@8&7>\Q:^@__1GRU: M;&&IA0+MA-'$0E/0^_1XVH?X&/ L8'2K,PF57(QY"<:7NJ!)$ 02*A\8.&Y7 M> I Q'*^#5STB5E *[/;^R?8NU8RX4[>##RIZA]5] #)34T?)#^R8R?8:[G MEI*Y^*]P!8GA00GFJ(QT<275X+Q1,PM*4?QUVH6.^SC=[.YFV#8@FP'9 CC$ M/&Q*%)4_RS0YY.P:B.:8TQ23 MK6.6"(;L2XIL*\4I^P^>;<-WFPIW$;[[1^'';8+])L$^$NS7!&GRKL2MF/=% MLE5/%=@V3I,CE1ETG.25=QG8^RR^R=_P:=J_<=L*['S9V/_&& \H);G! M$>KP@RV&A,:'XP<\VVG,)L.;?OY!;/G&Y1]02P,$% @ S5!N2ZO?$2>U M 0 T@, !D !X;"]W;W)K&UL;5-A;]L@$/TK MB!]08N)L561;:CI-F[1)4:=MGXE]ME'!YP&.NW\_P([K=OX"W''OW;OCR$8T MS[8%<.1%J\[FM'6N/S)FRQ:TL'?80^=O:C1:.&^:AMG>@*@B2"O&=[L/3 O9 MT2*+OK,I,AR9-.ZX&!%UHL&?H#[V9^-M]C" M4DD-G978$0-U3A^2XRD-\3'@EX31KLXD5')!? [&URJGNR (%)0N, B_7>$1 ME I$7L:?F9,N*0-P?;ZQ?XZU^UHNPL(CJM^R)RL:5E(-UJ&<6+T6+EVF77=S'Z>9P@VT#^ S@"^ ^ MB4 M*"K_))PH,H,C,5/O>Q&>.#ERWYLR.&,KXIT7;[WW6B0)S]@U$,TQIRF&KV.6 M".;9EQ1\*\6)_P?GV_#]IL)]A._?*-QO$Z2;!&DD2-\0I.]*W(HYO$O"5CW5 M8)HX39:4.'1QDE?>96 ?>'R3U_!IVK\+T\C.D@LZ_[*Q_S6B R]E=^='J/4? M;#$4U"X&UL;5/;;MLP#/T501]0 MQ4[69H%MH.DP=, &!!W6/BLV;0O5Q97DN/O[4;+KNIU?))'B.3RDJ&PP]MFU M )Z\*JE=3EOONP-CKFQ!<7=E.M!X4QNKN$?3-LQU%G@504JR=+.Y9HH+38LL M^DZVR$SOI=!PLL3U2G'[]PC2##E-Z)OC032M#PY69!UOX#?X/]W)HL5FEDHH MT$X832S4.;U-#L==B(\!CP(&MSB34,G9F.=@_*ARN@F"0$+I P/'[0)W(&4@ M0ADO$R>=4P;@\OS&_CW6CK6IGB^43,7_ MA M(# ]*,$=II(LK*7OGC9I84(KBK^,N=-R'\6:;3K!U0#H!TAFPCWG8F"@J M_\8]+S)K!F+'WG<\/'%R2+$W97#&5L0[%._0>RF2Y#ICET TQ1S'F'09,T

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end XML 43 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 43 127 1 true 23 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.entremed.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.entremed.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] Sheet http://www.entremed.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets [Parenthetical] Statements 3 false false R4.htm 104 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.entremed.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 105 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.entremed.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 106 - Disclosure - Basis of Presentation Sheet http://www.entremed.com/role/BasisOfPresentation Basis of Presentation Notes 6 false false R7.htm 107 - Disclosure - License Arrangements Sheet http://www.entremed.com/role/LicenseArrangements License Arrangements Notes 7 false false R8.htm 108 - Disclosure - Note Payable Sheet http://www.entremed.com/role/NotePayable Note Payable Notes 8 false false R9.htm 109 - Disclosure - Fair Value Measurements Sheet http://www.entremed.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 110 - Disclosure - Stockholders' Equity Sheet http://www.entremed.com/role/StockholdersEquity Stockholders' Equity Notes 10 false false R11.htm 111 - Disclosure - Net Loss Per Share Sheet http://www.entremed.com/role/NetLossPerShare Net Loss Per Share Notes 11 false false R12.htm 112 - Disclosure - Share-Based Compensation Sheet http://www.entremed.com/role/SharebasedCompensation Share-Based Compensation Notes 12 false false R13.htm 113 - Disclosure - Income Taxes Sheet http://www.entremed.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 114 - Disclosure - Related Party Transactions Sheet http://www.entremed.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 115 - Disclosure - New Accounting Pronouncements Sheet http://www.entremed.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 15 false false R16.htm 116 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.entremed.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.entremed.com/role/FairValueMeasurements 16 false false R17.htm 117 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.entremed.com/role/SharebasedCompensationTables Share-Based Compensation (Tables) Tables http://www.entremed.com/role/SharebasedCompensation 17 false false R18.htm 118 - Disclosure - Basis of Presentation (Details Textual) Sheet http://www.entremed.com/role/BasisOfPresentationDetailsTextual Basis of Presentation (Details Textual) Details http://www.entremed.com/role/BasisOfPresentation 18 false false R19.htm 119 - Disclosure - Note Payable (Details Textual) Sheet http://www.entremed.com/role/NotePayableDetailsTextual Note Payable (Details Textual) Details http://www.entremed.com/role/NotePayable 19 false false R20.htm 120 - Disclosure - Fair Value Measurements (Details) Sheet http://www.entremed.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.entremed.com/role/FairValueMeasurementsTables 20 false false R21.htm 121 - Disclosure - Fair Value Measurements (Details 1) Sheet http://www.entremed.com/role/FairValueMeasurementsDetails1 Fair Value Measurements (Details 1) Details http://www.entremed.com/role/FairValueMeasurementsTables 21 false false R22.htm 122 - Disclosure - Fair Value Measurements (Details Textual) Sheet http://www.entremed.com/role/FairValueMeasurementsDetailsTextual Fair Value Measurements (Details Textual) Details http://www.entremed.com/role/FairValueMeasurementsTables 22 false false R23.htm 123 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.entremed.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.entremed.com/role/StockholdersEquity 23 false false R24.htm 124 - Disclosure - Net Loss Per Share (Details Textual) Sheet http://www.entremed.com/role/NetLossPerShareDetailsTextual Net Loss Per Share (Details Textual) Details http://www.entremed.com/role/NetLossPerShare 24 false false R25.htm 125 - Disclosure - Share-Based Compensation (Details) Sheet http://www.entremed.com/role/SharebasedCompensationDetails Share-Based Compensation (Details) Details http://www.entremed.com/role/SharebasedCompensationTables 25 false false R26.htm 126 - Disclosure - Share-Based Compensation (Details 1) Sheet http://www.entremed.com/role/SharebasedCompensationDetails1 Share-Based Compensation (Details 1) Details http://www.entremed.com/role/SharebasedCompensationTables 26 false false R27.htm 127 - Disclosure - Share-Based Compensation (Details 2) Sheet http://www.entremed.com/role/SharebasedCompensationDetails2 Share-Based Compensation (Details 2) Details http://www.entremed.com/role/SharebasedCompensationTables 27 false false R28.htm 128 - Disclosure - Share-Based Compensation (Details Textual) Sheet http://www.entremed.com/role/SharebasedCompensationDetailsTextual Share-Based Compensation (Details Textual) Details http://www.entremed.com/role/SharebasedCompensationTables 28 false false R29.htm 129 - Disclosure - Income Taxes (Details Textual) Sheet http://www.entremed.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://www.entremed.com/role/IncomeTaxes 29 false false R30.htm 130 - Disclosure - Related Party Transactions (Details Textual) Sheet http://www.entremed.com/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) Details http://www.entremed.com/role/RelatedPartyTransactions 30 false false All Reports Book All Reports casi-20170930.xml casi-20170930.xsd casi-20170930_cal.xml casi-20170930_def.xml casi-20170930_lab.xml casi-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 48 0001144204-17-058708-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-17-058708-xbrl.zip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

>7VWM0'"?M[B9HLG"2IC"0)D;CWBVP6"QH M:6QS*Y%>DLH/'.Y_OR$EV;)$R7*2[>I.?2D4<;[AS#?4D$.3???30Q22.Y"* M"7[2&^SM]PAP7P2,ST]ZGR>7WH\]\M/IZU?O_N9YY -PD%1#0*:/Y()J.I'4 M_Z(R/!GL#?:."#[L'WG7XLX[V!_\0'[9/SQ^NW_\YO!7\N_AQ_^0][<3XI'[ M^_N] #5HJV'/%Q'QO--WRE] 1(FF<@[ZFD:@EM2'D]Y"Z^5QOV]0P+6$" *# MZ9L>]H\.C=4AON3Z4LCH F8T#O5)[X^8AFS&(.B1UZ_04:Z.?:I8$W6O7Q$+ MV)"]/]P3)C*,,,<]DWSE"K(0XQ$H%>@ M/.!M/VG<$ ]K]/]\A1T4E;,: .-*4^YO&E1R(G5[<'1TU+>M*+Z6CY4WIW2Y M0LRHFEKYM,&2ZNT/O,-!OAM?Q,C\XZ;C"OR]N;CKIXU5T%A*'*15V+2U AP M<^.PP4#>E"'PX"_<&--2T0_C=Z"T&Y:T&>!A&<@I\Y4;9YLJ^E/,=X.PP4 & M90@&2#\N03E#9UNJ^M)+6=$9ME3T%L!2@F^R1^6 /.I3Z4L1 EKB:P\>EB'E M5 OY>(E_;Y D.(\CMZ) R[ZQOH]"'DJ!9/X&=CLP!S*YCW(N,%5ABCM]1Y=+ MQF?"O#:?PK$Q=X(@8AX^?QI5)Q?KV(7P8Y.GACQXSS73CR-4)B.KO$<80<])^@%S?(D60\K[20_**2*J))*J^L;]B=4PQ3^L%:(;V- W%)L@9E\.G MQ(7\LJ'YUV[':46?NIG=+,V:#TVH^UPJ ,[XO&D6G[5*(F9DK?1;9#*BSZE: M7(;BOFE@UO+.N+Q]2ER,3F*5=B8N9UA"()OCG"M) %P-3J:_-[,T4WXH5"P! M_[!(0V<>VQE"KYAOQME02LKGR=!*"'4U. G]H4AHBB1Y:&?XO!8:QO213D-( M>,R_,Y4C"J>.]B]#!?I'0//#O)(%VALUKT%="J3'(VP6N6-,/ MO/#2R>.@])&#)@9&$$&69''!]A0A\@39WY%TX.#XL<)@AB(9WA[1.$9GF-5:A^G."B15$_5W15 MMCH9?5-D-(43BR=Y!9WA]QKNA[[=5V9\/I:"XZ.?G^+K!)PLORWGTWNR5D$V M=72&:.=2:6(6DG5KJ53 272I7*I849'O$BW_Z S7[JDJ3W:MA)/M4BU5-:5U MCVY'@7\!FK)03>!!Q]DNYG8Q)_&E(LRY*T"^2W615%EWZ,^5L2[:JYN==)?J MM'S-VV&6G>DY9:,F@6<2+JX/2B5<909/U7RCV[ PV,[WP$UXJ=;;1C@9?*.\ ME%&:"#KI+Y6%6^GO7)HI[_ZX(K!5RDE_J:)T[1AUF/O"=I%S,JT5<;)>JCK+ M^TNDPZ2[5^(;$VN]B)/T4A%:O5KOW-1:2^>@ >45DVNI'MW*>9=FUUI&#QJP M?N!F?8>Z-&/]X!OKCBFUB:0S J4"=7L$.I?E<[O=+O*KFYV,EVK4_-9XAUFN MV@YW4=Y0UL7_8:ENK=Y(__^(1G:JU?QC.U'O9R?G?T*&]ARC,1(SJF@/H-II%#M*.,Q7IF>#Z(^FH1"Q!:@:J MGQG?ZY\^WQ_D>U=_-D/4*F]".MW5&X1 V#I'<%SOZDCA4WA9=_K9N7!\6I\6 MQP;T1$A-N/,N2]5MC.0:S)7PK9H:B/G+RW">>>4-#KS#P=Z#"A+#=NA_Y=&. M_6>XW?IWWW1IV',&,%V^;=!9[:64BCYM?TY@'T*MLC?>6E53KVON@=39XH"E MS]Y:Q:XVN*[:-#$BC\O^> 85SEL[C>S( U=_/<.2TIV>)E:L0/;I&;V7K_@T MZ7Z-2AZ?84#QNE"3[C.,>?#6X)V[+EX>:M1W!K)/N_5>OG]D)PH.<[/(:Y:, M0BDW4"8C'9DD./C^.18T3(6YWO5S>ZZ_>]74FKR6]VLENQE7>S&OR:C(,.;! M6X-WY:5\(ZP)#474,P+COLNVFQ&"7[OM(,WGS/)MP*=/FE:7,T.E=WBM+?47 MX89396X.X[A,%HSVHNLQOF-\/M(0F6JF1V@J==+3,C;+22N%"S@F@HG%!;%, M3_YQ%H;FE]],5L4(9CHVK1^DB)=9)PS5)Y6E69'^ULC*_BDI.'>[@" .X69V M P;O M$^UV#><:+RJ#U4_,0QQ?D?V"U*60,T#C)7S"%46!)1^1K2#I99PK4WDE M^'P",AIQXRJ[@S&N(8Z;#J27XV%,TQMA'N'"([%?FFG\[/[A:7O3Z7XIZ?,:%\!I@;%":(UGP-U;:5_?A( M'U@41];AB3B#9.VS.8AQ40 ::7B9*"6BT_1*/IHL(6"ZN7<5%M'76M\<1CE3"7L M?(&2K3&[:%%U'= :DPL&.5:GN2_FEH:;7\N++GC^M.^^J0MEYR]@BNM990@R MBVQS4(&&)M6;W_ ^+P7/R/3F^:-%N M:]_6N-' 2%4H6?YK^HV631-_(3FR_,;Z(L,?DBM[F;6&#^ M@ZVOO"W4Q$9'G.?XG&+:\PFZK'*N^#=NMK2P--MNX@YNM6Z7>8NE6UUKT:1< M:=F63V:]V?B7[WM6V84>F&.-R<_\I_\%4$L#!!0 ( ,U0;DMWG =NG 8 M *=/ 5 8V%S:2TR,#$W,#DS,%]C86PN>&ULW5Q?;]LV$'\OT.^@N<^R M[+A=ZR!)X<1)82R-@]@9!@Q#04OGF(A$>B3MQ!OVW4?*]N(_I$0GF44%?8CC MWIWN[G=W/!ZI''U]3&)O"HQC2HXK]6JMX@$):83)W7'EMG_A?ZEX7T_>OSOZ MR?>];T" (0&1-YAY;210GZ'PGB_YO7JU7FUZ\D.MZ5_1J7]0JW_V?J\U#C_5 M#C\V_O#^;GW_QSOO]3W?>WAXJ$92@D@E5$.:>+Y_HKOW[@-^K51QY5 M3HX8C>$&AE[Z\$,Q&\-QA>-D'"NET^]&#(;'E1!QG#JXUFS4%.^',THB(!PB M^8'3&$<*J5,4*X-[(P#!*YZ2?GO363, B&"00*1 "!1!8",I.'GWVKKV9#A( M18C@W6%WK")-^OIE2IM$_L_:GR$^NHCIP^LIOR+Q9;KW! WO1S2.9,Z>_SG! M8F:KHXY3Z1*B.)S$J6!OQ<9C&)3)(/6. MO4I=KF,274SH-'3.XR)P4 3& =%@C%7 M\RP7A'4ZAYV_89#)Z8TBG:Y6+9FKZH?*URF*U6K6$F>(L9EL,7]%\00RP+#C M=P"DC;C:Q,K2#TY6L6L&8X2C\\>Q6I6E%2M9GY].-MSNXV?E _NR%VRT3'MJ MH@S-\%ZC2:[6';F_3."2\JRF:H-NS[U5APA@P!PB5& QQC@2$KN&PEE $Z2U_8%"=___T! MY7(9),O"FH79%JG[X&Q;9].D[1^%&^ @': ZE#9,(:;IOFJA=08DV7R%XF,* MK$V(Q6XM AB\Z7W+5"&39YK<(.0HK-GF< MNIE9NSC,R!:<.808CG[I6%.Z%,X+_27S-@RN(J M.6B9#G%R?OH-8:(BK$O:F(\IQTJ][C#W="2;K^0PYCC%S7:_-T(,3E':E"2J M9\K+0P-#R;$SN<$$VD>W9AZ+D60;AL 8Z$>3.XU K 26'//GNM$4$Y\*3>1M M:UIA2">J[T,S-(BS.O=\WC<']99S3*C^[%:F2[W9!*+GCC8U[&\1VBT7F=#] M7.AAFJPU'?(+)M%RZ)YU=K9-7'+D=.:;GO1 =VB\6)9]B+.R?90+G.[M(V,QR&?=\UV$G;37$!>:#+9 ;)VP M:"C=W"&PQ?@_U3COI00==:'XV".B-=1)2%;J9>Y+(IND)0%CVT0G)R:M*,)S MC>;3VS,TQD*I9P3$Q%$27(P&.[GUZ:N=W83-K%)%0UP24'1FVIS4%W&;6B!, M(#I'C,A.D;?"<)(HYX(Z9<8ASAHS63"7!# ;-]@.<)[;G.W\ M=LC^@:#DK@\LN:("+&XT:,E=@<:(@M9&)SLR[;F>U7OM>9RN@Y1KN9OI\Z1K M_FNZ&F+74='9YV2'MG'OR.)/$.@97 $DYUUID[E.%K7MBT-6\!AXRH.0R6@G M*]GJXI@/CXZZ),!H#76RIJG9!1;I 9,Z?*1$G2T#";.;YBPN5R#:J8G.=,-+ M9OOOY;^C__Z8W,F_4$L#!!0 ( ,U0;DMM.GCKS"8 (Y[ @ 5 8V%S M:2TR,#$W,#DS,%]D968N>&UL[5U9<^,XDGZ?B/X/WIIGERW)98D=W34A7SV. M<94=9=?T;FQL,&@2DCA-D6H>+GLV]K]O@CI,23A)@ !=]=+ML@$PO_QP)I"9 MO_SM>1X=/*$T"Y/XUW>]]\?O#E#L)T$83W]]]_7AZG#T[N!O'W_YC\/#@]]0 MC%(O1\'!X\O!A9=[#ZGG_Y&M:Q_TWO?>.P?PP[%S^#EY.NP?]X8'_WT\^/G# M\<\G@_\Y^-_QI_\[N+Q_.#@\^/;MV_L 6LC+%M[[R?S@\/#C3W_Y)0KC/QZ] M#!V 6''VZ[M9GB]^/CK"Y9\?T^A]DDZ/^L?'@Z-UP7?+DC\_9^%6Z6^#==G> MT7]^NKGW9VCN'89QEGNQ_UH+-T.JUW,CY1_?'6!]I4F$OJ#)02GJ MS_G+ OWZ+@OGBPA#+'\W2]'DUW>^EX4E().F\Q/?N +?[]'*^GR&4"P\]GL*DJ^J1.^TF(SV3\G.;KS7KS'"-4;A8P&FDEVY87I/[VH M0)^0EQ7I$OD#_HZP&IE-:)!.CL5XW%&VMX1J;)_X?LR0*X%1Q^6LS$3Y-?2CQXM:./M:5!7Z&I0'Z]F& )EX1Y0HEVV];B9S)W MC/6(NFVX@ M9=G X1S-'U&J4L2M=NO+-P-14K]X1(<;T JE)+5>7]8XR<=*!\JJP:./!S_] MY1?HD6$O,-S;YOBEOLG<5'+XNX DPCS[RN)XW1;9.A$ZT97_4EJ6IZDR5Q89>L/ M)T*2'Q09R)(L\._P4I*DL&P?_'KP#K9 RQ[[LY_$.73"RZA<'J'7HRG^X?7O M40*;^5_?Y6F!EJNE-&,3+WLLE5!DAU//6V#:ADG.>45[+OQG=+NJ'L,[$.@=;K*PS8(*A..9B:6I^$O:!IF M>>K%^6=O3IN*2$7=WG%W"* !H)_XCEO1_CFV5WC1=1R@YW^@%Z;Z=\JZO5[7 M]$] 0">@IYF \R)-MZ9&]FI,*^[V^MVA@06"SD3=X['<4+@*(Y2>@S#3)&4/ MA*V2;D^/E4+C,-B3GZ[Z@6;5/Z0>?F-W_S)_3"**TK?*N#U-A@<=ZMZ3G*[H MDW:F^V0^3^+R=%W>766W18Z? F(IV7,_HZ+;Z]!Q5PP.G:?5,?AH^X[@H_); M _YS/<&K@_U+4/P;]P)E?AJ6 &\G9T4&6LNR<1P0OLNZ-:C=E@O2B-ML*"#N M9R@H(G0[D9" =JG0K$&WK^=41KQW:*;TG4'1'+<=MQ:B$^$-FGK1[>(.]!T\./>/= 41UMF7N55?<.@ M3[6FKP]JZUCI)0%EP3F'_YS/PMC[M+4IV5U&=HJY(\?8#FFO(Q)F?Y*XRN\! M%-PJW_LH]M(P$;U1KI9W!WJL%69F<"Y4Y1<,#>A;B?8USA;(#R1 UT&/ZLF0)(\%5?SUB[FG.0-,>4,&+J<&>J8R-@W5I MTCE6K%NIFM+#7Z;**Z.&IC?\R>LL*U! F<](Q=R!GD<[9J8P&D(UURE\Q5/[ M.[F@.QQH>CK"G8*HFF(KM"(WZ^;$K$I-SQ^-=2LP7WQH?5];/&;HSP)&X.73 MZG$B;]M$K@$ ];Q8,[QK8J"ETVC@\+\O)_]82:OCCHY-67Z%]"Y,504.G:SV M30"JN3(],^HB36#";-\0L"TPWPY *@_@C+SI$APJ0E15D-#I,6 ) "G#(/32 MEWL/KP5"E@!:'7?HO*7[2#&\].O)]FT!%?GP2\[;2240 '_.Y%9V1R>:QJ'4 M0L?@@D*@&#(ZDZV;#UH@TJ954!.C_ 6QW]SB=B_;?,= "!YV] M5/_"V1.*-P):TW-:-KM)E%0 O0.T;PRI"LC=7.P7=AU-;UC$=X6RRN=36(%& MIZIU4X@"IFS9]NFD3&#?)V$(H:YX3RB#PIR=QTXQ$,^(7Q2OCQ-7L7W)Z0IM MWW3Q!?L=Q"BX]-(85M=L[/O%O"CA78!J_3!G#@Y>95>3@9Y#E-)']')HZ8^! M92P9E.%R!VLSEGD*R^[MMQBEV2Q<7, M-IEL )U.JXPK*8763]YS."_FY7)*\/_5SQ,YK\-!]-Y=]P3_7ZFAT!MD3";F($3$N52 MJ#XM,=2E>F M#UQJ_(@[FT^RLC=HS1T:L05J9;6A.I3$)*6&*F*(E&&CC(\7BC J\*W1*K4, M]95-G<;K],%U5A_>H]2-)MTQ7(SVF"-VF*WKL M?Z6JZ;KI2FWD@)'!X#=ZZ*5T(98&+#):-?5:'UD3!8>H:,H-$A&'/1:IYJ38 M8GM2QHZ%YJ;:2] FO>0XRXIYB23#>T8?-HG_3")H)L(AVLD1N%O\NJLKM5)K M!S/&$M^.^BRRJ2E%_"7,_KA*$5H_16JSLY*^[8ZZ;AEJJ:O2E&>;L7#O:+J/ M]U%F:#Z@=-[C]5 M'W5'73=O<;JF-JWI-'PJ'51723I!85ZDB#(/ZOZD.S)B M4=/:Q]K0F?+<3Y8LS^NA=!$^A0&* Q-[R>JWW9&15&'=6YYIRK/;7MS_82^N M]A7G1"*AQ/=H,';T& %U&XP=NE>:4MW883'6F\;"T6,W-&0'=O:,613,G[&62O%W);.$,3%MG:^O80BOL!9J@-*4.W-_#?'8=!W@[57C1 MWAB&<8UC>^&X (1FV)=T5XGL3E MFY.,#HM[)Z3N(ZZNA#'"%WQM= ]RQU2K18:%]4<7Y"C/](+YQOHB?QEO/^2K MTEL^ENNTW7C/\OPIT-;K*PVG;F76@'\#0KB?K!BOY33Q]J\@K9,4%=/B_"M*RS&0<:)RC"UT"C9G,= M6#U#T13&2L/4M2[X^C"EC2Y(^!IHU*AGN]U=D*8P5I:JKG7!U?R.[0W:3PA[ MWP)M=OWYKM89D*0NJW)KJ3L$_8["Z2Q'P?@)I=X4K;<==VGH:WG!)BI#TVUBD](;E2Y=CAZ]0@L4KDQ3A9).>I8K48 MX'Y3SQ-+&LE]90^V19&OUK)Q'[YM%P08FDP-PF\1][7*UGY%<'MB7#50ORUO M#NOSH-2/BA+AXB:)ISB4QG6,,XB%3PB+ <5Z[.R%G&H@O5&+!*E/;VM=&(5% M3D%?\%3+R[>[+N/V^F\J]P=C_=C&;%&,HE(P?DJ!UU( P/03]AUE,C1>$=D> M#Y%:*K=EJ:BC>_XB(9'25@T'GT![\V+.96&K'& Q:B+9Z])D[>_+S NZTJ;B MEVDF^8JOE@,09C,/"RI^3V:6YT7;FG$<[S(O3K:<99I8GE ]::U)BU\TR4S8V6\["Q4-RR0[K4+,ET(1IAVH&0X*4"D!D>1!\3US;L@%I M@W0!SSD),P/E6'N6P"QTGWN3R>UD$OHHS<9Q<#E?1,D+0AG[;"M2UQV934=3 M:[ 13L#"6*UZ2+_VXERZN^/%*8GQMW=599L60K5TR6P\+5N+EE.&/ 5SM2Y5<[M M#=Y4?A;&5+F/^VV\XWW%%0?"=RPZ/N>.3DU?E!$XIJR;NO"SWM'^Z%)U5&K+ M*F*\;_$7G7[K<4KN4#I)TKD7^VCI0LXU6%)J $"['S[7GA H5\0,-;RE=YU, MUYKRCQ>P.=M$1M?XOE-2$ACA7?>09KWI,J!,[GO/+G3KI4/N:J.:C9^\,,(; MSZLD+5'KZ+^<3X)NN_X@64='%=$:O4?:$M5$NC\!KL[G<)/M#25F.I?M6S7' M4=DX"LCRKM)%L\[H0@VX@].N>_4RN);0 9W[[L7E,!NY;Z#K"&]#C]*C+GKG MLR4NQVH)+/)9DH;_1L'7&"2LQ/K"IY9LRS^G?,AQDWQ#Z?*GKBT>;$;+^A9)IZBUGHWZIB\C=&M#IP\M1T?RS_NIZL> I;3$#V9&!33I8M M,Z1ZUFS,R_8U3I&?3&-LD83YY S%H.^<-352:KB]#T8S(-0V/['PE2(F%GW"[N]TYZQ]9\;-&^K M('0 /2L]._(=666$?U58COLI1GRWT^3)Q@>(2;J!/^ ^3FI\ ._439+?(]+64 M[KQ(4VQN%65BISR ,OH G*1B%ADD\2V*]';N9;-Q'.#_8?_?)R\J78671AS8 M*?/\5(3J VBCS[093)"I$T?%L&2U'O$U10LO#%9/A4'\VWR&TBWL#"(%:@-@ MHZ$T: NTL3L2V]1,+J[-(&=?OZ"[_]R'%4&9H %7H(_ M(_8 HE<#B$9]%\07+2X*FX+758;SYR3VN8.&6!Y0&7UR+1. M72"WT??'LONX4EZ;$L??A-YC&(':$ Y]5;X5G241R),M [D(;+!%FW![0[,O ME^.!RR4)G4W!W<:^GQ1P2KCS7K#-3V + M1ZP N(P:''@:I\R1="PVA60#,=,"!?L8V321ZP ZHY:(VDPQX-B4=OMSDB/Q MT40H[0Z/C9H=ZA%$ V)32FFI 43L:ATDAH+#IKAJZ[P@U3[$8H90W!WH>D+> MXJZ!ALNFO+\7* V?/)R\I0)9Z!C+J0E(C5J#5# H M&F5+<5*<5F0K>OZ9K: MS.:\A&-3)*_S9#X/\_*M/S;D;Y[]L EBU )%='Y>Y,&S*F95'8,&4RV=GQ0Y MZ&R*[W0';2&8JI=(>9>(A-* R&RT'XZNJ1=.1" VA6O"DT 2"_&R6Q2PF(U. M4HL4(@J;@BB-@R!!B!!FJVT'%D MVZ8#B^1M6@[2H#P-W:&TC"0C;-VB->#V'.O>6-&7" E,%CF@;$N]&W-1F,+= MB@#3\ FQ/G5$+!;YIY"DOE(K+$[RQ+ R+#EZ,RM- M<#U $[)=V3GM%=/5FQE+67 M(+I%-L/S)"L?.*_B?H@,"EH5T(+A9Z@R@X.)PB)KX1>4(5 $#K%S ;TH2LH( M$_Q$H129A0"^Y 5]X./?R)@[(I6@YTL667 MNTDR%FE;Y:!3VG9;S*!F7W2;@MNL'Z*O;]+.O"ST\;XGC(J<>0W"J0E(;;LA M9I D L:FJ#:_HW Z \'&3[#=F:)E)O#;22E[Y69;G,UZ#8)>;+M(9I#< ",W M6H[Y^Q<<%?4J2KYU[?JEWWK^C-K7+ST]1@?IZY<^PQ=Y3^+OXOJE9T&")Y+N M!:Y?>BRO5]NN7WJ:+ +UKE]ZQ/0->Q)WYOJEYUAY_2*F9@NO7V#KC5?%NS1Y M"F&U/7OY"M/8=;QZJ1!/QSZIBLJW:APV:?<=AL_P)H'/RKR)9Q;AZ2+PAV'7X8H2V1'Q)U U;'YT"E1D^U M:GN+-@U9=*EU@18I\L-EJNDX&,^3- __7?Z3T7<8M0"@V:P9VD@C=Q*>*FRZ M"@/]8?RW\468+9*LI.9VP@U]SJSG.F8O,-OFFZ\,BR[0R"GE64=Z8@70A]D4 M*BUSS-""3==QR\!#_PCC8'T_Q6!VO[#;UY4+STY6*1KX3J_O/GQ7W,NHQ:8+ MP'VY-PI8!1P3V.F+-P(J-)N2R7BW8&K&IIO)?=%7><,N5LZ288AR^M. M=;<_,&J)U4@M":E5Z4*$+59*;.^ _VV9&S*<<)R.XC%&17H KLB'([H>:L9!WBQ5MQ';//T^MR1CF[2P*W M*64*;"Q6)YJQ#T*FJ!;SPHV &HT:X!43+X?;INPJXHI0,K4#?J-&6K6\2^*V M*8D+1?2K,/9B7]'2SFC,=01F M=%(UP&CT0%:7%?8<3D5J5PZ8UYW&6M+;224>D.#VC%@7T-IX_*K+JQ!<-5ED M?"\K'Q$.CYW!<4D8_@UA7UCY_$-RAJCAJF2JN\Z)C<]:)&F31FQ3MAEQ%2A9 M3$%_;X#QFKAM2E^#Y<99W^!_>*?_!%T6VVI1&B;!KL&/P;Q,,V[_I$,;*&ED M-B7!(0L_AMZ:IB_0,;FIOD3J ^H.O3,6AV15%IQBL5BZQWC1VM/J.IXDZ7SY M,$X@":)8"X#<.IL9<6Y:^''UU-W'! 6C8LPPRY018I$8M8T M;!IT93;PDPRE]"'>6 7>E3&9ZSU,[O83[[&B>/&4J?\+WJ M=;PH\FS]IF/Y7A;^5:3IRJY[VG6 M&KU7RMCA*(<]JE[D9J+:;;FGIV;7GOI33S/,=%;;"J_[.HW:/[7O"KNX%A/ M/R5Z8G-40^J(/-GM\,EN$BFN3%EYYZ7YRT/JQ1D,)!SY^>RE^A>* [=\(Z S M/>N5D'^W&*/DU4@2HW)'<#444UV8Z84!CJ:'MEQ7\;JZYS-8@:;:I]PH4::] MSMM@3*E[.FV56R ?YN/YWLSQ41G[#=S! M234LY@P.N75!44:>:LJ=W.3@6.0$C46\CC.\^$)76_M^?H&%>YDJ[0X6$FQ3 MF;)NFL0;<0=FWN[48U,2EQKW9\K^<%<6T)P7K3O7UT42KQ^9T/:*P@VXCAD_ MQQJV$CE,-CDS;TM^!7M>F#H*YBMG6A7 9B2A@8HQM8/"?*HRTA5 5NZ'6XZ- MN1&DXJ"UDBFXW;EQV+N?V+Z>8-EN=7[.'8X^M+T7D<&!K>1G$?O58JWVW,$' MHY[BVLCDW9M)*XEES+:XYW"4IKICB7[.'9I-.&1SOY/2H46V=)48.5[NJC\% MU!G(.=GE3KC1&N.*H!.7?!NEG+UL?OQ[B%)@; MAT^-=8/ET[D2]X!ZKRE0"W :?6I68TQRV*5@Y(7"-6,-6;TQ^V$.D=U$#@96 MFT-L.ST,- 5/:__T@(EOZ_0P8(9=^W%ZJ"Z\ TU!V\R>'LH>T.CT,&!%>3-H M FEU'SD8:')T5'UZ*-E2L7W$B.UYFVB,]8Z='E32;V$>'M(>N5?K]-!;/R?X@=DXBUI)K&*T M**5-71?'C.+CR M"H.5[[L"LG[NQ0Z)R)?(2\!BU,/5^F)CD.Y'SP\0D<50> MZ'DO8<+$Q#\%J-3:#Q.3X.EL8-#%1V\/:&9B&C!>>WX_)B9-#GK*34P#JK.* M/.(?)J91UTQ,"NFWV<34\3.1'1:1MGQGM!"AD#@!#1<'C:^BN.C12\ _)V0?=D:.#] M-45EE,% D+CK1\L-I//(R]9QW7D1(FAU0",6O' FL<3ADPC$HA-?53[N!G^_ M,, Q_;B8HVHR/Q0D]IS)%/!BR^E*(4$6GIK:CN-V,M1SYZ-I(I1$9M&AHVE0 ML*&N@!TZHK>5NNVK.BJ2>.O MXF7VN)8W8!G"UUOC.+C EV5)F6OU\GD!2F*9Z9CU8/&T+?LTPW['AT+G:]"2 M%;H\2\^2"+Z;X;1!L/YVV/[L#%NWR=2U/P\U14R5M3]CE8G9GX>LH*C?I?UY M>*)G^6^R1QO24[BP@;PA^_/P1--I1H']N52UL'D3(WD[]F= 8\T63!U!K43 M7^<_1@%EMB(5 ^GL.T02)BBJ[$HLOWR54OLRN: [_&#*_96N*;9&*X*KL-%J M4:GIJ:&Y;I5:4]6=H<,@]-*79=)FH0T/K8X[ZMMWX<[:\#"!*#'"*F+I5;S/ MWAQ^K-CY^28/;F6 :X.=BD$%A3\Q9 S[[]OCT?0LV0*A N:LX\9K%4Z(&9W# M632,I^RKDOV2KM,WFQA:<%P0UBT*AWVG; OPXLWPZ>E>D_LS+T'B:HN5S M>,XM%;>FZWPP:Q&L3X4@.&[<]R;4K-("C./@'K^G#80&!+,2R&PD)XD"0OBX MN/;:3EXUCOH<#6V]718- ):C^PJ^*T39KB<36_:BSU+GMK-6*%T>JU_XI< M-5.P-RP*\3R[DA73#/1'-W,H2)$504)G9[VXZJT_1IV MI"DXIJ;U3!(9G=GV[19-7UF./IA.&RFK?#Z%%6ATJEJW3"A@RI8E32=E_.6M M+V%Z4'KK]KN7 MC\-OT23F:K$S"LR-'^Q*452#126O]D9H6SFR9)W60)S _2KQ*H!BEQE/L];V4@&,@ M)!0%,8T&>^!V?X+EB0:#KF4#YHSUG'WOH]A+PT3TV52U/*#2<\K2_61J#P2= MFO:]TM;"?8VS!?+#203L3>ZBPR2) H3.DPI<-7^,\)&=H M^=+F?N:EB/WX;;>P.S1\/RCTXIHC/UW'[7NX$;Z 53=$!5;+:'"+]Z6_[GG-W:>(C%&17H(UUZOC;R7DRGR=QV749 M)'/KNB.S,>OE"!6#0R>O?>-$]5:\P*J ?Y3SRW*NN8XKAC3!)TJ\9D '1@.1 M2_JZR"*CL]N^OT1%^'(ZN4-I*;P8DUM5 )O9[4E=UO91T!F2>:Q!V9E\1GF= M"5&XKCLRO$T4W[<(PZ$3TKXU@[@F;T;^YF76N1=%*#A[V5V>93 %S:@!2H"O(;C5TC M,3I%T=#9:/^)!TGF+,>BXL7^]UFXZ4^;67UUM.7XPS=K&/34<0N )%9ZGY"Q M 8GE/JJ*04=QVG Q,G%P'=C??8@L1/W8S+X70F+H>CR65:.BZ' M(QJ7PV$Y2G^7<3F<$PMR5Y-8XO!)!/*&XG(XQOSF!57-7+UWD;R=N!R.>>=[ M#019&!=:G<^6\T'/VT!=4QP#AD7AG=6Z 3F.\8L598]4(28JB#1&1)Z'/RKR/+R%/F0C(,@7'[DS@N#Z_C< M6X2Y%U4"VE"/_7+-0(^U[DY__U!5&QDOZK1V*\%GE-\D6;:^\ZQG'Z!?;U;; M9AW[F>5=9]0\5,1O*JN,S1MYM!.I$S_V=&,/683S7W E@.% MQ9W!0A/-;2G#->S%GE'PD)0;OG5H= %[C4AU0&XPC&+#-4(8H$5F'9[,W.$N MU@# -IVS7IR=>NQ6@-IC"FJ17EOF]/9XMM!\=#E?1,D+0N6)?(F$:T*BU@&, M1N/5R8PX,I=L:#9%N5T;9);H\*XCB;'-1?2BEU0/0.IY_M7&8LI'9E%NLQT9 MN;,JL;SKC$P'M1!0.F6@40$I"51K&4NV+'7JZ1*(8==ZKK/56S3N.K95#L 8 MM; S!@29DGWIU42WM<(8.9XG1CQ1AY92INPU:.ND2WM)_@EENK1 MR]#'_P=02P,$% @ S5!N2\=^SC=O- $M8" !4 !C87-I+3(P,3

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end